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ACCP   American College of Chest Physicians  
BS   Bronchus sign 
CB   Cryobiopsy 
CBCT   Cone beam computed tomography  
COLDICE   Cryobiopsy versus Open Lung Biopsy in the Diagnosis of  
   Interstitial Lung Disease Study 
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EGFR   Epidermal growth factor receptor 
FNA   Fine needle aspiration 
ILD   Interstitial Lung Disease 
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MDD   Multidisciplinary discussion 
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PPL   Peripheral pulmonary lesion 
RP-EBUS  Radial endobronchial ultrasound 
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TBB     Transbronchial biopsy  
TB-CB   Transbronchial Cryobiopsy 
TB-FB   Transbronchial forceps biopsy  
TBNA   Transbronchial needle aspiration  




Lung cancer is a leading cause of cancer-related deaths worldwide. This is no 
different in Australia where it is the main cause of cancer-related mortality, and 
the fifth most commonly cancer diagnosed in Australians.  
The recent National Lung Screening Trial demonstrated an improvement in 
mortality when patients deemed high risk for lung cancer underwent annual 
screening with low dose computed tomography imaging. Nearly 25% of 
participants were shown to have imaging suspicious for lung cancer. In light of 
these results, and with the possibility of increased uptake of screening, it is very 
likely that the incidence of identified peripheral pulmonary lesions (PPL) will 
only continue to rise. 
In evaluating PPLs, standard bronchoscopic investigation involves obtaining 
transbronchial forceps biopsies (TB-FB). However TBFB has variable 
diagnostic sensitivity, influenced by factors such as lesion size and position. 
The introduction of radial endobronchial ultrasound (RP-EBUS) has helped 
improve diagnostic yields further.  Ultrasound images obtained by the miniprobe 
reflect the underlying structure of the peripheral lesion being examined and RP-
EBUS is now a well-established technique in the evaluation of PPLs. 
The overall aim of this thesis was to examine innovative bronchoscopic 






(i) Radial Endobronchial Ultrasound Greyscale Texture Analysis Using 
Whole-Lesion Analysis Can Characterise Benign and Malignant 
Lesions without Region-of-Interest Selection Bias 
Custom software was developed to analyse RP-EBUS images based 
on first and second order greyscale texture features. Unconstrained 
ROIs were mapped onto lesions.  Features from expert and non-
expert defined ROIs were compared, as were results of image 
analysis to tissue histology.  
(ii) Radial Endobronchial Ultrasound with Transbronchial Cryobiopsy 
versus Radial EBUS alone for the Diagnosis of Peripheral Pulmonary 
Lesions 
Prospective, single-centre randomised controlled trials of patients 
with PPLs. Patients were randomised to receive either one 
transbronchial cryobiopsy (TB-CB) sample, or 5 TB-FB samples. 
Results 
(i) Greyscale texture analysis of RP-EBUS images using unconstrained 
regions of interest (ROIs) demonstrated 5 features which were 
significantly different between benign and malignant lesions. Highest 
positive predictive values were associated with maximal and range of 
pixel intensities. No significant differences were seen between expert 
and non-expert-defined ROIs.  
(ii) 28 lesions were evaluated with overall diagnostic yield 76.7%. 
Diagnostic yields of TB-CB and TB-FB were 91.7% and 68.8% 
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respectively (p=0.14). Median size of TB-CB was 7.0mm compared to 




Timely diagnosis of PPLs is critical to enable disease staging and to guide 
initiation of appropriate definitive treatment.   
Greyscale image analysis and texture analysis using the whole RP-EBUS 
image as a ROI can assist in distinguishing between malignant and benign 
lesions. This is a potentially valuable additional clinical tool in the diagnosis of 
peripheral lesions. However further validation is required.  
Cryotherapy has provided an alternative method of obtaining transbronchial 
biopsies (TBBs). Not only does it provide significantly larger biopsy sample, 
which is advantageous for further immunohistochemical and molecular 
analysis, but it also could be superior in diagnosing lesions which are not easily 









I certify that this work contains no material which has been accepted for the 
award of any other degree or diploma in my name, in any university or other 
tertiary institution and, to the best of my knowledge and belief, contains no 
material previously published or written by another person, except where due 
reference has been made in the text. In addition, I certify that no part of this 
work will, in the future, be used in a submission in my name, for any other 
degree or diploma in any university or other tertiary institution without the prior 
approval of the University of Adelaide and where applicable, any partner 
institution responsible for the joint-award of this degree.  
 
I acknowledge that copyright of published works contained within this thesis 
resides with the copyright holder(s) of those works.  
 
I also give permission for the digital version of my thesis to be made available 
on the web, via the University’s digital research repository, the Library Search 
and also through web search engines, unless permission has been granted by 
the University to restrict access for a period of time.  
 
I acknowledge the support I have received for my research through the 











This thesis, and all the results within it, would not have been possible without 
the help and assistance of many. I am greatly indebted to numerous people for 
supporting me throughout my candidature and respiratory training.  
My most important thank you is to my supervisor, A/Professor Phan Nguyen. 
This thesis truly would not have occurred without your ongoing encouragement, 
support and generosity. I am so privileged to have had the opportunity to learn 
from you, and sincerely wish I had more time to learn more.  I never would have 
envisaged myself as a proceduralist or undertaking a thesis but your 
unwavering support, patience and invaluable advice helped me with both. I am 
incredibly grateful to have had you as a mentor, and also as a friend.  
I am additionally very thankful to my other supervisors, Professor Hubertus 
Jersmann and Professor Mark Holmes. You have both been a significant 
source of advice, humour and persistent belief in me, especially during the 
more challenging times. I could not have asked for more supportive supervisors 
- not just during my candidature, but also throughout my respiratory training.   
I need to extend very sincere thanks to Dr Arash Badiei. This thesis would not 
have been completed without your significant contribution. I am so appreciative 
of your tremendous generosity in including me in your image analysis work. 
You are one of the most brilliant but humble people I know. 
I was delighted to have Dr Jennifer Ong as my initial postgraduate co-ordinator. 
Aunty Jenny, you have been like family to me. To have started this journey with 
your involvement made it so much less intimidating. Thank you to my 
subsequent postgraduate co-ordinator, Dr Karen Jones, for your gentle 
encouragement and support, especially when I was struggling to see the end 
result.  
To my dear friend and colleague, Dr Emily Hopkins, I cannot believe how much 
we achieved together. Knowing that I had you alongside me learning how to 
balance work, research, and life as new mothers made this so much more 
achievable and enjoyable.  
To my friends and colleagues from the Department of Thoracic Medicine at the 
Royal Adelaide Hospital, I could not have asked for a more welcoming unit to 
work with. There are too many people to mention, but special thanks to 
Professor Chien-Li Holmes-Liew and Dr Aeneas Yeo. I would not be where I 
am today without your friendship and guidance. Thank you to the incredible 
Thoracic Procedure Suite nursing staff  - particularly Sophie Winnicki, Corrina 
Mitchell, Lynda Doncaster and Julia Kim. You were always extremely patient 
with me, and made my time in TPS truly enjoyable. Thank you also to the 
wonderful Rosemarie Severino and Maree Oborn for assisting me with patient 





Finally I must give heartfelt thanks to my family. To my siblings – A/Professor 
Christopher Wong and Dr Nicole Wong, thank you for your love, support and 
also for all the last minute extra assistance with my research and statistics. To 
my parents, Dr Charles Wong and Mrs Siew Jee Wong – your guidance, work 
ethic and selflessness have enabled every opportunity I have had in life. I would 
not be the person I am today without your love and support, and hope to be the 
same type of parent to Toby and Gemma that you have been to me. Most 
importantly, I thank my husband, Gerald Sim. You sacrificed so much, and 






Publications included in this thesis/Statement of Authorship 
Chapter 2 
 
Radial Endobronchial Ultrasound Greyscale Texture Analysis Using Whole-
Lesion Analysis Can Characterise Benign and Malignant Lesions without 
Region-of-Interest Selection Bias  
 
Badiei A, Nguyen P, Jersmann H, Wong M  
 
Respiration. 2019; 97(1):78-83. Epub 2018 Oct 4. PMID: 30286457. 
 
Certification: This paper reports on original research I conducted during the 
period of my Higher Degree by Research candidature and is not 
subject to any obligations or contractual agreements with a third 




Radial Endobronchial Ultrasound with Transbronchial Cryobiopsy versus Radial 
Endobronchial Ultrasound Alone for the Diagnosis of Peripheral Pulmonary 
Lesions  
Wong M, Jersmann H, Holmes M, Nguyen P 
Unpublished – prepared in manuscript style for submission   
Certification: This paper reports on original research I conducted during the 
period of my Higher Degree by Research candidature and is not 
subject to any obligations or contractual agreements with a third 




CHAPTER 1.1: PERIPHERAL PULMONARY LESIONS  
 
Peripheral pulmonary lesions (PPLs) are focal parenchymal opacities typically 
recognised on chest imaging. These lesions can be further characterised by 
their size to be described in further detail as a pulmonary nodule (where the 
lesion is less than 3cm in diameter), or a mass (when larger than 3 centimetres) 
[1, 2]. By definition, peripheral lesions are completely surrounded by pulmonary 
parenchyma and cannot be visualised endobronchially during bronchoscopy [3]. 
There is no associated extrinsic compression on the bronchi, endobronchial 
lesions, narrowing, inflammation or bleeding of the bronchi when examined 
during bronchoscopy. The concern regarding these lesions are their potential to 
have an underlying malignant aetiology, with some high risk populations 
demonstrating prevalence of malignancy as high as 79% in PPLs [4].  It is now 
well recognised that that the larger the size of the PPL, the higher the 
probability that it may be malignant, regardless of whether it was detected 
incidentally or by screening [5-7].  
 
The incidence of identified PPLs is increasing, particularly in light of increased 
usage of computed tomography (CT) imaging generally, and also for lung 
cancer screening [5, 8, 9]. Previous data from the United States in regards to 
solid pulmonary nodules was not able to accurately determine prevalence, but 
estimated a detection rate of 150,000 to 1 million new cases per year [10]. One 
factor for the expected increase in identification of these PPLs was the results 
of the recent National Lung Screening Trial (NLST) where participants were 
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randomised to receive annual screening with either low-dose CT scans or chest 
radiography for three years [8]. Results demonstrated a relative reduction in 
mortality from lung cancer of 20% when screening for lung cancer was 
performed with low-dose CT. This resulted in a B grade recommendation by the 
US preventative services task force to screen high risk individuals yearly. 
24.2% of the low-dose CT screen group had imaging which was suspicious for 
malignancy, however it should also be noted that 96.4% of the detected 
nodules were subsequently found to be benign (i.e. false-positives). It was 
noted that as nodule size increased up to 30mm in diameter, so did the positive 
predictive value of a positive screen.  
 
1.1.1: Guidelines for Management 
 
To aid clinicians in the management of PPLs, several guidelines have been 
published over the last two decades, the most notable being those from the 
Fleischner Society [6, 11] and the American College of Chest Physicians 
(ACCP) [9]. Both of these recommend investigation and further management 
based on the patient’s pre-test probability of cancer.  
 
The Fleischner Society’s guidelines were specifically designed to address 
management of small pulmonary nodules which had been identified incidentally 
on CT imaging which had been undertaken for a reason other than screening 
for lung cancer. Whilst serial follow up will allow early intervention of those 
nodules which declare themselves to be likely malignant, the authors 
recognised multiple disadvantages of serial imaging. These included morbidity 
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and mortality from surgery for benign lesions, increased health care costs and 
poor utilisation of limited resources, increased patient anxiety, and increased 
radiation exposure [11]. They referenced results from large screening programs 
which showed that nearly half of all smokers aged more than 50 would have at 
least one nodule incidentally discovered on screening examination whilst 
approximately 10% of participants screened would develop a new nodule over 
a 1 year period [12]. Detection of new nodules during follow up periods would 
result in increased length of screening, and potentially further detection of new 
nodules.  
 
They therefore offered guidelines for management of smaller lesions, including 
which lesions to follow, and at which length of interval. Factors affecting pre-test 
probability of a nodule being malignant included smoking history, lesions size, 
whether they had a ground glass appearance versus being a solid lesion, and 
increasing age.  
 
The guidelines were revised in 2017 in order to reduce the frequency of 
unnecessary repeat CT imaging [6] The authors took into account patient risk 
factors, in addition PPL features which were considered high risk such as large 
size, irregularity or spiculated appearance, and upper lobe location. 
 
According to the ACCP, high-risk PPLs had at least 65% chance of having 





In the above described NLST [8], participants who were deemed “high risk” and 
appropriate for recruitment included those aged 55-74 years, with at least 30 
pack years of smoking history. For those who were reformed smoker, they also 
must have quit within the previous 15 years. 
 
The NELSON (Nederlands-Leuvens Longkander Screenings Onderzoek) trial 
[13] was a Dutch-Belgian lung-cancer screening trial which followed the NLST 
as the second largest randomised-controlled trial to demonstrate reduction in 
lung cancer mortality with CT screening. The main difference was the use of 
volume and volume-doubling time in NELSON to help direct management of 
PPLs. Participants underwent low dose screening CT at 1, 2 and 2.5 year 
intervals. Screens were considered negative, indeterminate or positive based 
on volume and volume-doubling times. They found that using this growth-rate 
assessment as an imaging biomarker resulted in fewer referral rates for 
additional assessments and markedly lower lung cancer mortality compared 
with no screening. The effects of screening on lung cancer mortality were also 
of higher benefit in women.   
 
Tanner et al [2]  performed a retrospective observational multicentre study of 
patients with pulmonary nodules for investigation and examined their 
management by community respiratory physicians. Inclusion criteria included 
patients aged between 40 and 89 years, referral to a respiratory physician and 
nodule size of 8-20 millimetres. Those patients who had previous diagnosis of 
cancer within 2 years of nodule detection were excluded. Definitive diagnosis 
was established from either tissue diagnosis or stability after two year 
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radiographic follow up. The authors noted that patients who were current 
smokers and those with larger nodules (16 to 20mm in size) were more likely to 
be referred for further invasive procedure such as biopsy or surgery.  
 
In the above study, of the 377 patients who were included, 25% had nodules 
which were ultimately found to be malignant in nature. Not unexpectedly, of 
those who were diagnosed with cancer, they were more likely to be current or 
former smokers. However, although the patients with malignancy were found to 
have overall significantly higher smoking pack year history, 67% of patients with 
nodules (regardless of its underlying nature) were recorded as having smoked 
previously. The authors also noted that whilst malignant nodules were 
significantly larger than those which were eventually found to be benign, there 
was however no reliable measurement threshold over which malignancy could 
be consistently diagnosed on imaging size alone. 
 
The paper noted the importance of the diagnostic investigation of solitary 
pulmonary nodules, given that 25% of the patients referred evaluation were 
found to be have cancer.  
 
1.1.2: The Australian Situation 
 
In Australia, lung cancer is the fifth most commonly diagnosed cancer in 
Australians, and also the leading cause for cancer-related deaths in both 
Australian men and women [14]. Higher mortality rates were seen for those 
people living within regional or remote parts of Australia, and for those with 
19 
 
lower socio-economic background. For Aboriginal and Torres Strait Islander 
people, lung cancer occurred more frequently, and at earlier age. This 
prompted an official enquiry into the efficacy, process and delivery of a national 
lung cancer screening program. The Report on the Lung Cancer Screening 
Enquiry [15] was subsequently released in October 2020. It recognised 
international evidence from the previously mentioned NLST [8] and NELSON 
trial [13] regarding the significant benefits of biennial low dose CT screening 
program. A two-step eligibility process was proposed using age, smoking 
history and risk assessment via the PLCOm2012 risk model, which estimated 6- 
year lung cancer risk[16], and was derived from the Prostate, Lung, Colorectal 
and Ovarian (PLCO) Cancer Screening trial[17] which included data on over 
80,000 participants who had ever smoked. It is the one risk prediction model 
which has been validated in an Australian population. Potential participants who 
meet eligibility criteria would be offered screening with low-dose CT. It was 
hoped that the Program could be fully implemented nationwide within a four-
year timeframe. It was also estimated that more than 12,000 lung cancer-
related deaths could ultimately be prevented in the first 10 year of the Program.  
 
1.2: Bronchoscopy for Peripheral Pulmonary Lesions 
 
Bronchoscopy has played a role in the investigation of peripheral lesions and 
pulmonary nodules for more than forty years [18]. Success with bronchoscopy 
however relies on the ability of the operator to firstly navigate the bronchial 
system to the PPL, and then to subsequently obtain a sample successfully from 




There are multiple different diagnostic procedures which could be performed 
during bronchoscopic investigation of peripheral lesions including bronchial 
washings, bronchial brushings and transbronchial biopsies.  The latter, with the 
assistance of fluoroscopic guidance, has become the most conventional 
bronchoscopic sampling method for obtaining tissue diagnosis from these 
lesions since the 1970’s [3]. Diagnostic yield however for all these procedures, 
even when performed in combination, can be vary variable at 30-60% and 
sometimes even suboptimal [20, 21]. 
 
1.2.1: Bronchial Washings 
 
In a retrospective study by Cortese et al [22] published by Chest in 1979, the 
authors reviewed 48 patients who had undergone flexible fibreoptic 
bronchoscopy for primary lung cancers which were endoscopically invisible. 
They found that bronchial washings added no further information to 
transbronchial biopsies and brushings. Of the 28 patients who had abnormal 
results from bronchoscopic procedure, the bronchial washings were only found 
to be abnormal when the biopsies and/or brushings were also abnormal.   
 
Other studies noted that positive diagnostic yields from bronchial washings did 
not exceed 40%, when used in the investigation of solitary pulmonary nodules 
[20, 23]. In Baaklini et al’s 4 year retrospective study of flexible fibreoptic 
bronchoscopy in evaluating pulmonary nodules [20], the yield from washings 
was 40%, however for 7 of these patients, the diagnosis would have been 
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missed but for the washings positive yield. These included 4 malignant and 3 
benign conditions. Given that bronchial washings are not technically difficult to 
obtain, add very minimal time to procedure duration and very little extra cost, 
the authors argued that they were a valuable tool to utilise to increase 
diagnostic yield. It should be noted however, that even whilst positive washings 
might contribute towards diagnostic yield, they are typically insufficient for 
further ancillary tests such as molecular analysis and PDL-1 staining.  
  
1.2.2: Bronchial Brushings and Biopsies  
 
Performing the combination of both bronchial brushings in addition to  
transbronchial biopsies was found to optimise overall diagnostic yield with 
results as high as 79% and was recommended as early as the 1970s for 
investigating both central (visible) and peripheral lesions [24].  
 
In the previously discussed study by Cortese et al [22], the authors showed that 
the two methods were complementary to each other. Results demonstrated an 
overall higher diagnostic yield with biopsies. However there was note of 7 cases 
where bronchial brushings were abnormal, but the corresponding biopsy 
sample was normal. Thus the additional use of brushings was seen to increase 
the overall rate of abnormal results by 14% for this particularly study.   
 
In Kvale et al’s study [24], bronchial brushings were shown to have superior 
diagnostic yield over forceps biopsies in central tumours which could be 
visualised endoscopically. The authors attributed this result to the fact that a 
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brush could access increased surface area of the tumour and therefore have 
increased chance of obtaining malignant cells. Conversely the biopsy forceps 
with its small tip could only sample one small portion of tissue, which could also 
be adversely affected by crush artefact.  
 
The improvement in diagnostic accuracy with combination of bronchial 
brushings and biopsy was also seen in Yoshikawa et al’s study where 
transbronchial biopsies obtained by endobronchial ultrasonography (EBUS) 
with a guide sheath (GS) as a guide were used to investigate peripheral lesions  
without the assistance of radiographic fluoroscopy [25]. A more recent 
retrospective study by Minami et al, again investigating transbronchial biopsies 
also showed that performing the combination of transbronchial biopsies, 
bronchial brushings and washings together provided greater diagnostic 
sensitivity than just biopsies alone [26].  
 
Ost et al utilised results from the AQuIRE (ACCP Quality Improvement, 
Registry, Evaluation and Education) Registry to perform a multicentre study of 
patients undergoing transbronchial biopsies for investigation of peripheral 
lesions. They aimed to assess the diagnostic yields achieved by different types 
of bronchoscopy, typically performed in everyday practice [27].  Overall 
diagnostic yield by bronchoscopy was 53.7% (312/581 lesions). Transbronchial 
biopsies was successful in 43.2% (251/581 lesions), and was the sole 





1.2.3: Transbronchial Biopsies with X-ray Guidance 
 
Fluoroscopic guidance during transbronchial biopsies is well known to help 
improve yield [28, 29] and transbronchial biopsies has long been the most 
common diagnostic bronchoscopic procedure for patients being evaluated for 
solitary pulmonary nodules [9].  Transbronchial biopsies were first introduced in 
the mid 1960’s as a diagnostic procedure which could be applied clinically 
during the assessment of diffuse parenchymal lung diseases. Andersen et al al 
[30] noted that when flexible forceps were passed down rigid bronchoscopes, 
they were deflected towards the upper lobes and occasionally normal lung 
parenchymal tissue would be sampled without causing any subsequent adverse 
effects to the patient. Following the introduction of flexible bronchoscopes, 
transbronchial sampling became widely accepted as a safe and relatively non-
invasive method of lung biopsy.  
 
The procedure involves insertion of thin flexible forceps down the working 
channel of a bronchoscope. This is passed through the bronchoscope out into 
the region of interest. Because this area is typically beyond what can be 
visualised via the bronchoscope, fluoroscopic x-ray guidance is usually used to 
help guide the biopsies. A second operator assists the bronchoscopist to open 
and close the cup of the forceps in order to obtain the tissue.  
 
The importance of having fluoroscopic guidance to assist in diagnosing lesions 
suspicious for lung cancer was established very early on. In 1975, Zavala [31] 
described outcomes of 600 patients who underwent flexible bronchoscopy for 
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investigation of radiology or clinical features which were suggestive of 
bronchogenic carcinoma or diffuse pulmonary disease. Of the 330 patients 
(85%) with primary lung cancer, 42% had lesions which were not visible 
endoscopically, emphasising the value of fluoroscopic guidance.  
 
However, even with the assistance of imaging to guide biopsies, diagnostic 
yield for peripheral lesions is still highly variable. Previous studies have shown 
sensitivities for transbronchial biopsies to vary from as low as 14%, to higher 
than 70% [3, 22, 23, 28, 29, 32, 33]. Size and location of the lesion are both 
known the influence yield [9, 23, 34]. For nodules less than 2 centimetres in 
size, sensitivity with transbronchial biopsies can be as low as 14% [23, 33]. 
Conversely, in a meta-analysis by Wang Memoli et al [35], sensitivity was found 
to increase to 63% when nodules were larger than 2 centimetres, but also 
decrease as the location of the lesion from the hilum increased. Complication 
rate with transbronchial biopsies is generally low, but the use of fluoroscopy 
does result in radiation exposure to both the patient and the procedural staff [5, 
9]. 
 
1.2.4: Peripheral Transbronchial Needle Aspiration  
 
Transbronchial needle aspiration (TBNA) is another minimally invasive 
procedure, typically used with EBUS to sample mediastinal and hilar lymph 
nodes for diagnosis and staging. However conventional fluoroscopy-guided 
TBNA also has a role in diagnosing PPLs. Mondoni et al [36] recognised its 
importance, especially for centres which did not necessarily have the resources 
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or specific skills required for some of the more recent innovative bronchoscopic 
techniques. They conducted a systematic review and meta-analysis assessing 
the accuracy of conventional TBNA for PPLs, and to also identify factors which 
could positively affect diagnostic yield [36].  
 
The authors identified 18 eligible studies, with overall pooled diagnostic yield for 
TBNA of 53%. When compared directly to TBB, TBNA showed higher 
diagnostic yield. Further sub-analyses also demonstrated improved yield with 
malignant lesions, lesions larger than 3 centimetres, lesions associated with a 
positive CT bronchus sign, and when there was presence of rapid on-site 
evaluation (ROSE). 
 
The results of the AQuIRE Registry [27], as mentioned above, also recognised 
improved diagnostic yield with TBNA for PPLs. The authors also commented 
that it was an underutilised technique, with their data demonstrating usage in 
only approximately 16% cases. After adjusting for co-variates, they found that 
use of peripheral TBNA was the one factor amenable to physician control that 
improved yield. TBNA was diagnostic in 47.4% of their PPLs (45/95), and was 
also the sole positive test in 6.3% cases. The authors did note one particular 
limitation with TBNA which could explain its less frequent use. PPLs located 
within the upper lobes, or superior segments of the lowers lobes might not be 






1.2.5: EBUS as Alternative To Fluoroscopy 
 
The development of a miniaturised ultrasound probe in the early 1990’s has 
provided another tool in improving diagnostic yield in the investigation of 
peripheral lesions.   
 
Herth et al were the first group to apply EBUS to guide transbronchial biopsies 
in the investigation of peripheral lesions [18]. They performed a prospective, 
crossover trial with 50 patients receiving both fluoroscopy-guided and EBUS-
guided transbronchial biopsies.  They noted distinct changes in ultrasound 
images when the probe was introduced into a solid lesion as opposed to when 
it was within normal air-filled alveoli. Typically, when surrounded by normal lung 
tissue, a snow-storm type appearance was produced representing the 
ultrasound being completely reflected by air within the lung [18, 37]. However, 
the difference in impedance between normal lung parenchyma and pulmonary 
lesions resulted in a change in ultrasound picture. Lesions which were solid in 
nature such as PPLs and masses were typically dark and hypoechoic in 
appearance, with a bright border (hyperechoic lines) which differentiated the 
lesion from the surrounding lung [5, 37]. Areas of atelectasis or inflammation 
typically demonstrate a more heterogeneous image on ultrasound representing 
the different structures within the lung. Fluid also appears dark on imaging. 
Essentially, EBUS allowed examination of the different layers of the bronchial 
wall and its surrounding structures, which has made it another valuable 




EBUS has also been shown that it can be utilised for image guidance in 
obtaining transbronchial biopsies, either as an alternative to fluoroscopy [18, 
25, 38], or where lesions were fluoroscopically invisible [39]. Having 
acknowledged that size and location of PPLs significantly affected diagnostic 
sensitivity of transbronchial biopsies, and that nodules smaller than 3 
centimetres were frequently not able to be seen with fluoroscopy, Herth et al's 
group [39] aimed to assess diagnostic yield in these fluoroscopically invisible 
lesions.  Of the 54 patients with lesions meeting these criteria, the EBUS was 
able to localise the lesion in 48 patients (89%) and establish a definitive 
diagnosis in 38 patients (70%). Mean diameter of the lesions in this study was 
2.2 +/- 0.7cm. The authors commented that the procedure was easily learned 
and added little extra procedural time. The efficacy of EBUS in guiding 
transbronchial biopsies meant that procedures need not be aborted simply for 
lack of image guidance, and also helped avert the need for surgical referrals.  
 
The characteristics or pattern of the EBUS image can also help provide 
information in the underlying internal structure of the lesion, and even help in 
differentiating its nature. Kurimoto et al [40] was the first to examine the internal 
structure of  PPLs as by their images obtained with EBUS. The images were 
compared to their eventual histopathological diagnosis, with the objective of 
creating a classification system which could be used to speculate on a lesion’s 
underlying histology as based on their EBUS characteristics. The authors 
aimed to distinguish between benign and malignant disease, the subtype of 
cancer in the latter, and also the degree of differentiation. By focusing on the 
presence of internal echoes, the architecture of bronchi and vasculature, as 
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well as the morphology of hyperechoic areas (which reflected air, and the state 
of bronchi), three classes of lesions were identified. 92% of the type I lesions 
were benign, whilst 98 and 99% of types II and III were malignant. They 
concluded that this further information obtained during EBUS could further 
assist in suggesting the underlying nature of the lesion being investigated. 
 
1.3: Alternative Diagnostic Methods for Investigating Peripheral 
Pulmonary Lesions 
 
1.3.1: Surgical Resection 
 
Surgical biopsy procedures such as video-assisted thoracoscopic surgery have 
been applied in some institutions to investigate smaller peripheral lesions. 
However, this is a much more invasive procedure compared to bronchoscopy, 
and would be less preferable in those patients with poor respiratory status, or 
those who are elderly [3].  
 
In the ACCP’s 2013 updated guidelines on the management pulmonary 
nodules, they recognised that the gold standard for both treatment and 
diagnosis of malignant nodules was surgery [9]. However the authors also 
recognised that this option should only be taken with full consideration of the 
benefits, compared with the surgical risks. Their recommendations (Grade 2C) 
for surgery included those patients with solid, indeterminate lesions greater 
than 8mm in diameter which either had high pre-test probability for cancer 
(>65%), were FDG-PET positive, had suspicious non-surgical biopsies for 
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cancer, or where the patient preferred a definitive procedure. Where surgical 
diagnosis was chosen, there was recommendation (Grade 1C) for thoracosopic 
wedge resection as the preferred approach, being less invasive, and with lower 
risk than open thoracotomy. 
 
In Tanner et al’s  retrospective multicentre study of management patterns of 
solitary pulmonary nodules[2], 77 patients (20%) underwent a surgical 
procedure as their most invasive investigation. Of this subgroup, cancer was 
diagnosed in 50 patients (65%), meaning that 27 patients (35%) underwent 
surgery for benign lesions. The authors noted that whilst surgery was generally 
only recommended when pre-test probability of cancer was high (as a negative 
biopsy would still lead to surgery for definitive diagnosis, and positive biopsy 
result would also lead to surgery), and that the risk models evaluated in their 
study were generally good at excluding cancer, rates of surgical resection were 
still performed at rates as high as those with higher cancer risk. There was also 
no difference in surveillance patterns when stratified by pre-test risk, which 
suggested that physicians generally did not follow guidelines. However whilst 
pre-test risk did not appear to affect decisions regarding surveillance or surgery, 
there was a trend towards positive correlation between risk and biopsy 
(p=0.07). The authors acknowledged there was likely to be a multitude of 
factors, which in addition to pre-test probability, influenced their management 
decisions regarding pulmonary nodules however identifying these factors was 





1.3.2: Computed Tomography (CT) Guided Fine Needle Aspiration  
 
Transthoracic fine needle aspiration (FNA) of pulmonary lesions is another well-
established procedure, especially for lesions that are situated peripherally and 
closer to the pleura.  Sensitivity with CT guided FNA has been as quoted as 
high as 96% [5]. However, this technique can be associated with a relatively 
high risk of post-procedural adverse effects. Peri-procedural pneumothorax was 
the most common complication with rates ranging from 15-44% of which at 
least 15% may require intercostal chest drain insertion [5, 9].  
 
Fielding et al[23] performed a non-randomised prospective analysis of 140 RP-
EBUS cases, and compared these to a retrospective review of 121 CT FNA 
cases. Overall diagnostic sensitivity for the two procedures were similar at 66% 
and 64% respectively. However, complication rate differed significantly with 
pneumothorax rate and need for chest drain insertion was 1% and 0% for RP-
EBUS patients respectively, as compared to 28% and 5% for CT FNA patients 
(p<0.001 for both).  
 
In a large retrospective study by Yeow et al, risk factors for complications such 
as pneumothorax and bleeding were identified by examining 660 consecutive 
cases of CT guided lung biopsy [41]. 155 patients developed pneumothorax 
(23%). On multivariate analysis, the factors associated risk of pneumothorax 
were lesion size <2cm (pneumothorax rate 33% compared to 17% for those 
>2cm), lesion depth (lesions touching the visceral pleura had a negligible 
pneumothorax complication rate, whereas the further away the lesion was 
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noted to be located from the pleura, the higher the incidence of pneumothorax) 
and radiologist experience. Bleeding complications occurred in 201 procedures 
(30%), however the majority of these were only mild). 4% (26/660) were of 
moderate severity where the patient presented with small-volume haemoptysis. 
Lesion size and depth were again seen to be significant factors in increasing 
risk of bleeding.  
 
1.4: Radial Endobronchial Ultrasound  
 
The application of ultrasound within an endobronchial setting was first 
described in the 1990s by Hurter and Hanrath [42, 43]. By using small sized 
catheters originally designed for vascular examination, the authors noted these 
were useful in the examination of patients with bronchial stenosis, or with 
peripheral lesions which were endoscopically invisible [43]. EBUS allowed 
differentiation of bronchial cancer which had poor echogenicity, to normal 
bronchial wall and lung parenchyma which was highly echogenic. They were 
among the first to suggest EBUS as a possible alternative to fluoroscopy for 
finding peripheral lesions as well as recognising its other advantage of being 
able to identify large vessels near lesions to avoid.  
 
Whilst EBUS is still a relatively new bronchoscopic diagnostic technique, its 
value in identifying peripheral lesions and improving diagnostic yield with 




Fielding et al [23] were the first to formally compare the utility of radial EBUS 
(RP-EBUS) to CT guided lung biopsy. They recommended using the former, 
especially when the lesion was not in contact with the visceral pleura as RP-
EBUS had significantly reduced pneumothorax rate, and higher diagnostic yield 
when considered independently.  
 
This modality is particularly useful for small peripheral lesions, and even those 
which cannot be visualised on fluoroscopy [18, 39, 40]. Huang et al described 
RP-EBUS as the most effective method for investigating peripheral pulmonary 
lesions [45].  
 
The procedure involves the insertion of a flexible ultrasound miniprobe within a 
transparent sheath through the working channel of a fibreoptic bronchoscope.  
Once the latter cannot be advanced any further, the miniprobe is passed into 
the more distal bronchi towards the lesion. When turned on, the ultrasound 
transducer rotates producing a 360 degree radial ultrasound image [46]. This 
image subsequently assists the proceduralist to confirm whether the scope is in 
the correct position, and ideally within the lesion of interest. The surrounding 
tissue has different ultrasound characteristics pending different densities of 
normal and abnormal lung tissue, allowing identification of the target lesion [37]. 
If this is the case, the ultrasound miniprobe can then be removed whilst the 
sheath is left in place, following which the sampling instruments such as forceps 
or brush can be inserted and passed down into the lesion for sampling. The 
advantage of this technique is that the location of bronchoscope can be 
confirmed with real-time visualisation and essentially, the guidesheath  is 
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utilised as an extended working channel in order to maintain the location during 
biopsy[35]. 
 
Use of the guidesheath – a thin plastic tube, with a radio-opaque mark distally 
at the tip, was first reported by Kurimoto et al [47]. The guidesheath was 
developed in order to help maintain the position of the bronchoscope within the 
airways, and the authors noted several of the benefits conferred by it use. It 
allowed the repeated sampling into the same bronchial branch as identified by 
EBUS, thereby increasing the reliability and yield of the biopsies. There was 
also reduced bleeding risk, as the opposition of the guidesheath’s outer surface 
“snug” against the bronchus wall would allow blood to drain into the sheath 
instead of the proximal airways post biopsy [47]. Also, without a guidesheath, 
repeated insertion and manipulation of a miniprobe or sampling device could 
cause increased friction against the bronchial mucosa with subsequent oedema 
which could hinder further attempts at correct insertion [47].  
 
The first meta-analysis which specifically assessed the efficacy and factors 
influencing performance of RP-EBUS in evaluating PPLs was Steinfort et al in 
2011. They demonstrated a pooled sensitivity of 73% (range 49-88%), from a 
total of 1420 patients across 16 studies [46] 
 
Multiple studies assessing diagnostic yield of RP-EBUS were subsequently 
published, and a much larger meta-analysis which included 7872 lesions across 
57 retrospective and prospective studies was published by Ali et al in  2017 
[48]. This remains the largest meta-analysis to date, and confirmed the high 
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performance of RP-EBUS in assessing PPLs with an overall diagnostic yield of 
70.6% (range 49.4-92.3%). Subset analysis of the 4605 malignant lesions 
demonstrated overall yield of  72.4%  
 
As such, RP-EBUS is recommended by the ACCP clinical guidelines [49] as an 
adjunct image modality for patients with peripheral nodules suspicious for lung 
cancer. The authors noted that the real time confirmation of bronchoscopic 
sampling increases diagnostic yield as opposed to conventional bronchoscopy 
[49]. 
 
1.4.1: Visualisation with Radial EBUS  
 
Tay et al [44] retrospectively reviewed 196 patients who had undergone RP-
EBUS procedure to determine what factors would influence visualisation with 
RP-EBUS. In this study, a definitive tissue diagnosis was obtained in 55.6% 
(109/196) patients using a combination of bronchial washings, brushings and 
transbronchial biopsies.  Overall EBUS visualisation yield was found to be 79%. 
When looking at primary malignancy however, visualisation yield was increased 
at 83% (110/127 cases) with a diagnostic sensitivity of 69% (88/127). The 
authors noted that there were three factors on multivariate analysis which could 
significantly affect diagnostic yield: lesion size, malignancy and distance of the 
hilum from the lesion.  Lesions which were larger than 2cm had significantly 
increased visualisation yield compared to smaller lesions (85% and 63% 
respectively, p=0.0022). EBUS visualisation of malignant lesions was also 
higher (85%) compared to the visualisation rate in benign lesions of 66% 
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(p=0.0025). As size of benign and malignant lesions in this study were fairly 
similar, particularly in the <2cm category, the authors argued malignant lesions 
typically had a higher EBUS visualisation yield due to more distinguishable 
appearance on ultrasound imaging. This was in comparison to benign lesions 
where the borders were often much more ill-defined. Ultrasound appearances 
of the latter were often more subtle, especially in inflammatory conditions, 
making it more difficult to distinguish from surrounding normal lung tissue.   
 
Other literature confirmed that the visualisation yield from Tay et al’s study of 
79%, as well as its overall diagnostic yield of 56%, was very comparable to 
other studies. Earlier prospective study by Yoshikawa et al [25] of RP-EBUS 
investigation of PPLs without using fluoroscopic guidance, found that most of 
the PPLs  in their study could be visualised clearly with EBUS (75.6%). The 
mean diameter of the 123 lesions included was 31mm.  Kikuchi et al [3] also 
demonstrated that EBUS could detect 79.2% of peripheral lesions, all of which 
were <30mm in diameter (mean 18.4mm). 
 
Visualisation with EBUS is relevant as there is a very strong association 
between visualisation of the lesion and subsequent diagnostic yield [3, 18, 25, 
39, 44, 45, 47, 50]. If the lesion is not visible with EBUS, this makes the 
eventuality of a diagnosis being made minimal, with diagnostic yields quoted as 
low as 0-30% [3, 45, 47, 50]. In Tay et al’s study, those lesions which were 
visibly identified with EBUS had significantly higher diagnostic yield (66%), 
compared to those lesions which were not seen with EBUS (diagnostic yield 
20%) with p value of 0.00001 [44]. Steinfort et al [1] also agreed that location of 
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the lesion with RP-EBUS resulted in a significantly higher diagnostic yield in the 
first randomised controlled trial of EBUS guided transbronchial biopsies versus 
CT guided biopsy.  Of the 32 patients randomised to undergo EBUS, diagnostic 
yield was 100% when the lesion was located by the ultrasound probe versus 
50% when it was not (p=0.001). It was also demonstrated that the ability to 
locate the lesion was significantly associated with a subsequent diagnosis of 
primary lung cancer, and that RP-EBUS was more likely to be diagnostic in lung 
cancer compared to alternative diagnoses. Similarly, of the patients with 
primary cancer being investigated with EBUS, a positive correlation was noted 
between being able to locate the peripheral lesion with EBUS miniprobe and 
subsequent diagnosis (p=0.006).  
 
1.4.2: Diagnostic Yield  
 
The diagnostic sensitivity of RP-EBUS for detecting malignancy in a peripheral 
lesion has been shown to vary within individual studies. Generally however in 
randomised studies, the diagnostic yield of transbronchial biopsies taken with 
RP-EBUS for both malignant and benign lesions was between 70 and 85% [23]. 
Even without the use of fluoroscopic guidance, Yoshikawa et al were able to 
demonstrate a diagnostic yield of 61.8% with EBUS alone [25].  This was 
preceded by Herth et al’s study [39] which demonstrated that even where 
lesions could not be visualised on fluoroscopy, a diagnostic yield of 70% could 







Position of the probe in relation to the lesion has also been shown to be 
important in influencing diagnostic yield. Of most particular relevance, was 
whether the miniprobe of the RP-EBUS could be positioned centrally within a 
lesion [47, 50, 51].  In Kurimoto et al’s prospective study of RP-EBUS in 150 
patients with peripheral lesions, highest yield was achieved when the probe 
could be advanced into the lesion (87%) as opposed to the situation where 
EBUS image showed the probe to be adjacent to lesion, resulting in yield of 
42% [47]. In assessing diagnostic yield from transbronchial biopsies alone in 
the same scenarios, yield in the former was found to be very significantly 
increased (82% and 7% respectively, p<0.0001). 
 
Yamada et al [50] noted similar results in their subsequent retrospective study 
of RP-EBUS in small PPLs, measuring <30mm in mean diameter. For lesions in 
which EBUS image demonstrated the probe positioned within the lesion, a high 
diagnostic yield of 83% was achieved.  However diagnostic sensitivity of RP-
EBUS fell when the probe was positioned adjacent to the lesion (61%), and was 
significantly worse in the cases where the probe was completely outside the 
lesion (4%, p<0.001). On univariate analysis, both lesion size (mean diameter 
less than 15 millimetres) and probe position were found to be significant in 
influencing diagnostic yield. However on subsequent multivariate analysis, only 
probe position was noted to be significant. Position within the lesion only had a 
trend towards significance onmultivariate analysis (p=0.064). Given this, the 
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authors recommended advancing the probe to either within or adjacent to the 
lesion to optimise yield of biopsy.   
 
Yield was also affected, dependent upon whether the peripheral lesion was in 
contact with the lung’s visceral pleural location as shown by Fielding [23]. 
Identifying whether there was any contact with the visceral pleura was found to 
be relevant, to guide which diagnostic procedure to choose (CT guided biopsy 
versus RP-EBUS) in order to maximise yield and minimise complications. In the 
RP-EBUS group, 117 of the lesions were not in contact with the pleura 
compared with 23 lesions which were on the pleura. These were associated 
with highly significant eventual diagnostic yields of 74% and 35% respectively 
(p<0.001).  
 
Effect of lobar position was also assessed in several studies with differing 
opinions. Huang et al [45] did not find any effect of lobar position on diagnostic 
yield.  In Yamada et al’s study [50], the authors did document that the 
percentage of peripheral lesions diagnosed by EBUS was slightly higher when 
situated within the left upper lobe, right middle and lobe lobes however these 
findings were not significant (p=0.66). Similar findings were seen by Yoshikawa 
et al [25] with significantly higher yields obtained from lesions within the right 
middle lobe (90%) and lingula region (80%), but much lower yield from the right 
upper lobe and right lower lobe (<0.05).  In the prospective study of RP-EBUS 
in nodules smaller than 20mm by Eberhardt et al [52],  highest yield (83%) was 
seen from right middle lobe lesions (p=0.02) with lower yields from right upper 
and lower lesions. Right upper lobe lesions were also found to be associated 
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with lower diagnostic yield from studies by Herth [18] and Shirakawa [38]. 
Yoshikawa proposed that this location may be more difficult to access by the 
EBUS scope tip which was relatively long and stiff, and harder to manoeuvre 
through this part of the lung which generally had tortuous airways with many 
acute angles [25]. Their rationale for the lower yield obtained from lesions within 
the right lower lobe was the risk of the EBUS sheath being dislodged from the 
lesion with deep respiration. Conversely, as it was often easier to identify 
airways directly leading into the right middle lobe and lingula, this helped to 
account for the increased yield of lesions within these regions.  
 
Whilst Steinfort et al’s study also did not find lobar location to affect diagnostic 
sensitivity of RP-EBUS, they did observe note a trend towards significance for 
yield, depending on how far away the lesion was located from the pulmonary 
hilum [1]. Of lesions situated less than 6cm from the hilum, positive diagnosis 
was made in 20/21 cases, compared with 5/8 lesions located more than 6 cm 
from the hilum (p=0.058).  
 
1.4.2.2: Presence of Air Bronchograms 
 
The presence of an air bronchogram was also described in Fielding’s study to 
be more likely associated with positive diagnosis [23]. Of the 24 patients in 
which an air bronchogram was identified on CT imaging, specimen positivity 
was seen in 20 (83%). The authors stated that the identification of an air 
bronchogram suggested that the pathologic process was peribronchial, in which 
case a transbronchial method of sampling the lesion was more likely to be 
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appropriate than a transthoracic approach. His study also showed that relatively 
more positive diagnoses were made in benign lesions compared to malignant. 
This was opposite to what was described earlier, whereby malignant lesions 
generally were easier to visualise with EBUS, and therefore found to have 
higher associated diagnostic yield. However the most common aetiologies of 
the benign lesions in Fielding’s study were noted to be  cryptogenic organising 
pneumonia, sarcoidosis, and focal collapse. All three of these pathologies are 
typically bronchocentric in nature and would therefore explain why they could 
be easily accessed via bronchoscopy. 
 
In Yoshikawa’s study of RP-EBUS without fluoroscopy [25], they also found 
significantly higher diagnostic yield if a bronchus leading to access of the 
peripheral lesion could be seen or presumed from the CT imaging. Of the 53 
lesions where a bronchus providing access was identified, a positive diagnosis 
was subsequently made in 42 cases (79.2%). Conversely, for all the lesions 
where accessibility was not evident, no diagnosis was made.  
 
Minezawa et al also assessed the relationship between target lesions and the 
nearest bronchus and identified 3 different types of CT bronchus signs [53].  A 
Type A CT bronchus sign (BS) was where the bronchus was seen to clearly 
extend into the peripheral lesion. A Type C CT BS was where no bronchus 
could be detected related to the lesion, and Type B encompassed all those 
lesions which could not categorised as Types A or C. They showed that the CT 
BS was the most important predictive factor for successful diagnosis of small 
PPLs, with diagnostic success rate for a Type A lesion 11.1 times higher than a 
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Type C. The authors noted that diagnostic yield was 88% for CT BS Type A 
lesions which were also visible on fluoroscopy, and this increased to 98.6% for 
malignant lesions. They concluded that thin-section CT and evaluation of CT 
BS could help determine which patients were most suitable for bronchoscopy. 
 
The correlation between BS and increased diagnostic yield of RP-EBUS for 
PPLs has been further supported in other studies [25, 54, 55] 
 
1.4.2.3: Size  
 
Lesion size is well recognised to correlate with diagnostic yield with 
transbronchial biopsies in general, and this is also the case with RP-EBUS, with 
sensitivity typically being lower for smaller peripheral lesions [50]. Diagnostic 
yield has been shown to vary depending on whether the lesion in interest is 
larger or smaller than 2 centimetres. Yang et al [56] looked at EBUS guided 
transbronchial biopsies in peripheral lung cancers.  They found that for lesions 
greater than 2 centimetres, diagnostic yield was 66%; however this was 
reduced to 55% when the lesions were smaller. In Yoshikawa’s study [25], 
similar findings was also shown was significantly increased yield (p<0.01) for 
lesions greater than 2 centimetres in diameter. Kikuchi et al [3] also showed 
that smaller lesions with mean diameter less than 2 centimetres had a lower 
diagnostic yield. Even in restricting yield to lesions less than 2 centimetres in 
mean diameter alone, the authors were still able to show diagnostic sensitivity 
for RP-EBUS as high as 53.3% (8/15 lesions), with 6 lesions (40%) being 
diagnosed on histopathology.  Multivariate analysis in study by Tay et al 
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showed that lesions greater than 2 centimetres which also had shorter distance 
from the hilum (less than 5 centimetres) were associated with improved 
diagnostic yield [44]  
 
Interestingly, in Steinfort et al’s study comparing the evaluation of peripheral 
lesions by RP-EBUS versus CT guided biopsy, lesion size was not shown to 
influence the diagnostic performance of EBUS [1].  In Schuhmann’s 2013 
review of RP-EBUS for peripheral lesions, range of yield was quoted between 
61 and 80% regardless of lesion size [5]. 
 
1.5: Operator Experience 
 
Yamada’s study [50] assessed factors which would influence diagnostic yield 
with RP-EBUS, included evaluating training and experience by the 
proceduralists. They demonstrated that there was no significant difference to 
diagnostic yield amongst operators who had performed more than 11 
examinations, and with more than 4 years of general bronchoscopic experience 
and training. The RP-EBUS procedure requires two operators – the 
bronchoscopist who holds the sheath in place after the correct area for biopsy 
is identified with the miniprobe, and another operator who manages the biopsy 
forceps and brush. The authors explained that as long as there was 
coordination between the two, and at least one person was familiar with the 
biopsy process with RP-EBUS, the procedure was relatively safe with good 




1.6: Number of Biopsies 
 
Optimal number of biopsy samples in conventional forceps transbronchial 
biopsies was assessed by Descombes et al [57] who assessed diagnostic yield 
by retrospectively reviewing 530 consecutive transbronchial biopsies from 510 
immunocompetent patients performed over an 8 year period. They found direct 
positive correlation between number of transbronchial biopsies obtained per 
procedure and the overall diagnostic yield. They recommended that a minimum 
5-6 transbronchial biopsies be obtained per procedure in order to improve 
overall sensitivity of transbronchial biopsies. For investigation of localised 
lesions and stage I sarcoidosis, increased number (7-10 biopsies) was 
recommended, however the authors recognised this was then associated with 
increased risk of complications.  
 
Other authors assessed the use of transbronchial biopsies in the 
immunocompromised population, also making similar general recommendation 
that given the small surface area of samples obtained by forceps, that at least 
6-8 samples be taken to ensure adequate material for diagnosis [58-62]  
 
The same issue has also been addressed for RP-EBUS. In the retrospective 
study by Yamada et al, they assessed the cumulative diagnostic yield following 
each consecutive biopsy, to determine the ideal number of specimens to obtain 
[50].  Whilst they observed that absolute yield obtained varied dependent upon 
the underlying disease, the overall size of the lesions studied, position of probe, 
and stepwise increment in cumulative diagnostic yield was similar amongst the 
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cases.  The authors subsequently showed that after 10 sequential biopsies 
were achieved, diagnostic yield of RP-EBUS for peripheral lesions increased to 
100%. By taking at least 5 sequential specimens, this would correlate with 
achieving more than 95% diagnostic yield. As such, the authors made the 
recommendation that a minimum of 5 specimens be taken during RP-EBUS.  
 
Their rationale behind obtaining needing multiple biopsies for smaller peripheral 
lesions was that the guidesheath may not always remain well seated within the 
lesion, in which case several biopsies are required. In the situation where the 
probe was positioned adjacent to the lesion, repeated biopsy was required. This 
was to help break through the benign bronchial mucosa in between the probe 
and the lesion, before the lesion could be accessed.  Also in patients with 
patients with benign disease, not all tissue samples may be truly representative 




One of the largest benefits of the RP-EBUS to obtain transbronchial biopsies is 
its well-recognised safety profile [44]. The safety and efficacy of RP-EBUS has 
been well established [38, 39].The complication rate associated with RP-EBUS 
has been found to be the lowest compared with other modalities for lung biopsy 
[46]. 
 
Complication rates for both pneumothorax and bleeding post transbronchial 
biopsies with RP-EBUS have been shown to be both approximately 0.5-1% [39, 
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46, 47].The low bleeding rate can be attributed to the ability to tamponade the 
bronchus following biopsy with the guidesheath which is left in place after the 
biopsy has been taken. In Kikuchi et al’s study of RP-EBUS for peripheral 
lesions [3], they noted there was occasionally coagulated bloods and less than 
1ml of bleeding caught within the guide sheath post biopsy, however there was 
minimal blood outside the guide sheath even after its removal from the 
bronchus. This ability to wedge the guide sheath against the bronchus for 
bleeding control would be the main reason bleeding complication rates are 
minimal.  
 
The largest study to date assessing complications was a retrospective review of 
965 patients who underwent RP-EBUSRP-EBUS for investigations of PPL over 
a 2 year period [63]. The authors defined a major complication as an event 
which either resulted in the procedure being ceased prematurely, or the 
development of symptomatic post-procedural sequelae. Only 13 patients (1.3%) 
were documented as having major complications. Of these, there were 8 
instances of pneumothorax (0.8%) of which 3 patients required chest drain 
insertion. 5 patients developed pulmonary infection (0.5%) and there were no 
cases of significant bleeding. All patients with complications improved with 
treatment. There were 4 probes which broke during procedure, but none of 
these were associated with any adverse effects. These results reinforced the 






1.8: TRANSBRONCHIAL CRYOBIOPSY 
 
Cryoprobes have had a role within bronchoscopic procedures as early as 1976 
[64] where their primary use was a debulking tool. The extreme cold properties 
of cryotherapy were initially utilised for its devitalising effects. After application 
of the cryoprobe to endobronchial tissue, necrosis would develop after several 
days, following which further procedures could be carried out to remove the 
dead tissue.  
 
Subsequent modifications in cryotherapy technology resulted in increased 
freezing power and increased tensile strength of the cryoprobe [64]. This 
allowed another form of debulking technique, utilising the frozen probe’s 
adhesive effects.  In this context, the proceduralist was able to freeze 
endobronchial tumour directly onto the cryoprobe, allowing for the tissue to be 
subsequently extracted and removed. This further type of debulking technique 
was termed cryorecanalisation. 
 
More recently, the observation was made that the endobronchial tumours 
extracted using this cryorecanalisation technique was of remarkably good size 
and quality, despite being frozen and unfrozen. Hetzel et al were the first [64] to 
question whether tissue removed using this technique could be utilised for 
further histological analysis. Since then, cryotherapy has been further 





1.8.1: Larger Biopsies 
 
One very useful advantage of cryotherapy is the ability to obtain generally 
larger specimens than those taken with conventional forceps biopsy. In the 
above mentioned study by Hetzel et al [64], the authors retrospectively 
analysed 12 biopsy samples which were harvested from prior 
cryorecanalisation procedures of endobronchial lesions. Quantitative digital 
assessment was performed on the specimens, revealing median sample area 
size of 3.5mm2 (range 1.4-14.1mm2) and median diameter of 6.7mm (range 
4.2-13mm). In their discussion, the authors commented that the size of the 
tissue samples achieved with this procedure exceeded that from any other 
bronchoscopic technique and that a freezing process of approximately 5 
seconds did not significantly prolong procedure time.   
 
Schumann et al [65] were one of the first groups to prospectively evaluate the 
safety and efficacy of cryobiopsy versus forceps biopsy in a large cohort of 
patients with endobronchial lesions.  296 patients were recruited in total over 
the 6 year study period. The first 55 received both cryobiopsy and forceps 
biopsy, with the sequence of biopsy procedure randomised, and the 
subsequent patients received cryotherapy alone.  Biopsy specimens from the 
patients receiving both procedures were assessed using quantitative image 
analysis. Sections from the biopsy samples with the least amount of damage 
and with the best preservation were chosen to evaluate both size and quality. 
They demonstrated that significantly larger mean total tissue areas were 




In a subsequent retrospective review assessing the safety and utility of 
cryotherapy in the investigation of all types of endobronchial lesions (both 
exophytic and flat), similar results were seen when assessing  volume of biopsy 
material [66]. Rubio et al showed that the mean volume of tissue obtained with 
cryobiopsy, was significantly larger than those taken with forceps. Of the 31 
patients included in this study, 22 received both cryobiopsy as well as 
conventional forceps biopsy, with the mean volume of material obtained in the  
former (0.696cm3) found to be significantly larger than those achieved with 
traditional forceps (0.0373cm3) with p value 0.0014.   
 
The authors recognised that other studies tended to report on size of tissue 
area, but they chose to analyse volume. Whilst they could not assess effect of 
biopsy depth on overall diagnostic yield from their results, they appreciated 
there would be circumstances where the smaller conventional forceps would 
not achieve adequate depth to biopsy deeper located malignant cells. For one 
of their cases, an exophytic tumour was nearly completely removed from the 
first cryobiopsy taken, with very high volume of biopsy material (1.25cm3).  
 
The efficacy of cryotherapy in transbronchial cryobiopsy was most apparent 
earliest in the evaluation of patients with diffuse parenchymal lung disease. 
Similar to its results obtained from analysis of endobronchial biopsies, 
transbronchial cryobiopsy samples were shown to have mean diameters 2-5 
times larger than those by conventional forceps biopsy [67, 68] and with 3-4 




Babiak et al [69] were one of the first groups to examine feasibility and safety of 
transbronchial cryobiopsy during flexible bronchoscopy. They retrospectively 
reviewed data from 41 patients who received both transbronchial forceps 
biopsies as well as cryobiopsies within the same procedure. They observed 
significantly larger median sample area from the cryoprobe, compared to the 
forceps (15.11mm2 vs 5.82mm2, p<0.01). 
 
In a subsequent randomised clinical trial of 77 patients being investigated for 
interstitial lung disease, Pajares et al [67] demonstrated significantly larger 
mean diameter, sample area, and number of alveoli sampled for cryotherapy, 
compared with the conventional forceps groups (p<0.001).  
 
Griff et al [70] also reported on a prospective case series of 15 patients who 
underwent transbronchial cryobiopsy. These were compared to a control group 
of 18 patients who received traditional forceps transbronchial biopsies. The 
authors commented that the cryoprobe produced samples which were much 
more representative of real lung structure. Similar to the other studies, 
specimen size in the cryobiopsies was significantly larger (mean 17.11mm2) 
than those which were taken with forceps (mean 3.8mm2) with p <0.001. There 
was also a trend towards more alveolar tissue being obtained with cryobiopsy 





Schumann et al [71] were later the first group to apply cryotherapy to the 
investigation of peripheral lesions, using RP-EBUS to guide transbronchial 
cryobiopsies. 39 patients were recruited; however one patient was 
subsequently excluded because of endobronchial disease. The remaining 38 
patients were scheduled to receive both cryobiopsies and forceps biopsies via 
RP-EBUS in a randomised order. Similar to results seen from the ILD studies, 
size of the tissue samples obtained with cryobiopsy were nearly 3 times larger 
than those taken with traditional forceps with mean sample areas of 11.18mm 
and 4.69 mm respectively.  
 
1.8.2: Higher quality specimens 
 
Because cryobiopsies are generally larger than those obtained with 
conventional forceps as described earlier, this provides the pathologist with 
more tissue in order to perform histopathological analysis, and potentially also 
further molecular studies. This is particularly relevant, especially in today’s era 
of personalised lung cancer treatment [64, 66]. 
 
However the other advantage is the quality of the specimens achieved with 
cryotherapy. Cryobiopsy samples are typically not exposed to crush artefacts 
which is common with forceps-obtained biopsies. Forceps crush artefacts occur 
secondary to mechanical compression of the lung parenchyma from the tip of 
the forceps. This results in alteration and poor preservation of cellular 
architecture within the tissue sample which can adversely affect histopathologic 




Cryobiopsy samples tend to have larger artefact-free tissue areas or, in some 
studies, have been found to be completely artefact-free [66, 68-70, 73]. They 
have generally good preservation of tissue architecture and cellular structures 
making them overall histologically superior, and of better quality than those 
achieved with forceps.  
 
Hetzel et al [64] demonstrated this in their review of exophytic endobronchial 
malignancies extracted with cryorecanalisation.  They found that all 12 
specimens showed well preserved cellular structures, and that the integrity of 
the different tissue layers were all maintained. 9 of the 12 samples examined 
had more than 75% biopsy area devoid of any artefact, with the remaining 3 
samples showing 50-75% unaltered tissue area. The authors commented that 
the high quality of the specimens obtained allowed easy and detailed 
subsequent histopathological assessment. The authors attributed these findings 
to the lack of mechanical and compressing which typically cause crush artefact 
with forceps. As the lung tissue was frozen before being removed , there was 
no artefacts secondary to tearing during the extraction process. They also did 
not observe any freezing artefacts.  
 
In a prospective study by Pourabdollah et al [73] comparing conventional 
forceps transbronchial lung biopsies to cryobiopsies in patients with diffuse 
parenchymal lung disease, specimen adequacy was determined by either the 
assessment of a minimum 50 alveolar spaces within the sample, or positive 
diagnosis being obtained. In considering these criterion, a significant difference 
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was seen, with 97% of samples achieved with cryobiopsy found to be adequate 
compared to just 63.4% specimens with conventional forceps. Pathologists who 
were blinded to the study also graded the percentage of artefact-free alveolar 
spaces in 25% intervals. A higher percentage of cryobiopsy specimens  (55%) 
were found to have more than 75% artefact free biopsy area, which was 
comparable to Hetzel et al’s study [64].  
 
Pourabdollah did however make note of a new artefact which seemed unique to 
cryobiopsies. They described a finding of ciliated columnar epithelial cells within 
alveolar spaces which had no connection to the lining cells [73]. This was 
observed in 7 out of the 40 specimens. The authors emphasised that 
pathologists would need to be familiar with this particular artefact, otherwise 
misdiagnosis with other pathologist such as adenomatous metaplasia could 
occur.  
 
In the first prospective study of cryotherapy in lung transplant recipients, 
Yarmus et al [74] compared transbronchial biopsies by conventional forceps to 
cryoprobe for assessment of transplant surveillance. Prior to their report, there 
had been no data assessing the safety of cryobiopsy in lung transplant 
recipients. The mean specimen size was significantly larger with cryoprobe, 
with significantly increased percentage of open alveoli. Additionally, all the 
specimens obtained with cryobiopsy were free of crush artefact whilst 
conversely, all samples taken with forceps biopsy showed significant amount of 
crush artefact when examined. There was no freezing artefact on any of the 
cryobiopsies. The authors stressed the importance of achieving higher quality 
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specimens, especially in this particular population of patients, where accurate 
diagnosis and early treatment of acute cellular rejection can potentially help 
reduce further risk of chronic rejection and increased mortality.  
 
1.8.3: Diagnostic Yield  
 
In Rubio’s retrospective review of cryobiopsy versus forceps biopsy for 
endobronchial disease [66], analysis of the 22 patients who received biopsies 
with both techniques showed a 100% diagnostic yield with cryobiopsy, and 
95.4% yield with forceps. Overall diagnostic yield for all cryobiopsy specimens 
was 96.77%. One sample only revealed evidence of necrotic debris resulting in 
no diagnosis.  
 
Similarly in Schumanns’s prospective study evaluating feasibility and safety of 
cryobiopsy for endobronchial tumours [65], cryobiopsy achieved a diagnosis in 
89.1% patients, compared to 65.5% with forceps in the group of patients who 
received both techniques (p<0.05). In evaluating all 296 patients who received 
cryobiopsy, overall diagnostic sensitivity was found to be 89.5%. 
 
Comparable findings were seen in Hetzel’s et al randomised multicentre trial 
[75]. In looking at the subgroup of patients with proven malignant disease, 
cryotherapy showed a diagnostic yield of 95% (268 of 282 patients) compared 
to 85.1% (239 of 281 patients) with conventional forceps (p<0.001). For the 56 
patients in whom a definitive diagnosis was not made at bronchoscopy, 
alternative procedures (including surgery) were performed. Upon evaluating 
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diagnostic yield of the different techniques for all patients, cryobiopsy was still 
significantly higher than forceps (95.2% vs 82.2%, p=0.0001). However, when 
rigid bronchoscopy was used under general anaesthetic, there was only a trend 
towards increased yield with cryobiopsy. The authors suggested that this was 
likely the case as the reduced breathing amplitude under general anaesthetic 
allowed easier positioning and use of the forceps, subsequently reducing the 
advantages achieved with cryobiopsy. However, the larger size, and better 
quality of the cryobiopsies still attributed towards their overall superiority.  
Additionally, the authors noted that there were less non-diagnostic results in 
patients with lung cancer following cryobiopsy then compared to after forceps 
biopsies. This observation seemed to suggest that cryobiopsy was more 
sensitive and more reliable in regards to diagnostic yield.  
 
In Schuhmann et al’s [71] more recent study of RP-EBUS and cryobiopsy for 
peripheral lesions, 4 of the cases which were non-diagnostic with forceps 
biopsy had positive diagnosis on cryobiopsy. This resulted in a yield of 74.2% 
for cryotherapy, compared to 61.3% for conventional forceps with RP-EBUS. 
The authors explained that as the cryoprobe was able to freeze all tissue 
surrounding its tip, this allowed biopsies to be obtained even in lateral 
directions. This was of particular advantage, especially in the situations where 
the EBUS probe cannot be advanced directly into the lesion. Of the 4 lesions in 
Schuhmann’s study where diagnosis was only achieved with cryobiopsy, the 




More recently, Nasu et al performed retrospective review of peripheral lung 
cancer cases with the aim of comparing efficacy of cryobiopsy using RP-EBUS 
to conventional forceps biopsy. Forceps biopsies were performed first, followed 
by cryobiopsy with RP-EBUS [76]. 53 patients were evaluated with median 
lesion size 32 mm and positive BS present in 92% cases. There was no 
significant difference found between diagnostic yields of forceps biopsies was 
86.6% compared to cryobiopsies with 81.1% (p = 0.60). Mean sample size 
obtained by cryobiopsy was significantly larger at 14.1mm2 compared to 
2.62mm2 (p<0.001). Univariate analysis showed that cryobiopsy with guide 
sheath had significantly higher yield than without guide sheath (95.8% and 
69%, p=0.15). On multivariate analysis, a positive BS was associated with 
increased diagnostic yield of cryobiopsy with RP-EBUS.  
 
1.8.4: Lesion Position 
Kho et al specifically evaluated the performance of transbronchial cryobiopsy vs 
forceps biopsy in eccentrically and adjacently orientated RP-EBUS lesions [77]. 
A target lesion was described as concentric where the probe was completely 
located within the lesion, whilst a lesion was classified as eccentric when the 
probe was still located within the lesion, but more biased towards one side. 
Only 43% (49/114) lesions had concentric orientation whereas the other 57% 
(65/114) were seen as eccentric or adjacent to the radial probe. Cryobiopsy did 
not increase the diagnostic yield significantly for concentric lesions compared to 
the forceps group (85.7% vs 77.1%, p=0.501). For the 48 eccentric lesions, 
diagnostic yield was 80% for cryobiopsy vs 56.3% with forceps biopsy (p = 
0.114). Of the 18 adjacently orientated lesions, cryobiopsy increased diagnostic 
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yield to 66.7% (6/9 cases) from 22% (2/9) with forceps (p=0.058). In combining 
eccentrically and adjacently orientated lesions together, there was a significant 
increase with cryobiopsy from 48.8% (20/41) to 75% (18/24) with p<0.05. 
However, these results needed to be considered in light of the fact that this was 
a non-randomised study with study design compounded by selection bias. In a 
subgroup of 24 cases where patients underwent both conventional forceps and 
cryobiopsy, diagnosis was only obtained by cryobiopsy in 43.8% cases.  
 
The advantage of the cryoprobe with adjacent lesions, with its ability to obtain a 
sphere of tissue from its frozen tip and therefore take lateral biopsies as 
opposed to just sampling in a forward direction has been previously described 
[71, 78] In Kho’s study, 57.2% of inconclusive forceps biopsies from 
eccentrically and adjacently orientated lesions were found to be bronchial 
epithelium [77] and the authors commented this was likely to due to too 




The feasibility of RP-EBUS-guided cryobiopsy without fluoroscopy was 
assessed in a small retrospective review by Chang et al [79]. 11 patients were 
included, with 6 of these undergoing bronchoscopy for diffuse parenchymal 
lung disease, and the other 5 being investigated for PPLs.  There were no 
major complications recorded. Pathological diagnosis was able to be obtained 
in 9 patients. Of the 2 patients who had pathology negative for malignancy, one 
was later confirmed to have non-small cell lung cancer from CT guided lung 
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biopsy, whilst the other patient did not return for follow up and remain 
undiagnosed. Whilst this study only had very small sample size, with limited 
generalisability of results, it did suggest that select PPL cases could be 
sampled with EBUS-guided cryobiopsy at centres without fluoroscopy 
equipment, however further study into this was required.   
 
1.8.6: Cryobiopsy without Guide Sheath 
 
The importance of guide sheath had been described above in Nasu et al’s 
study [76] where it was associated with increased diagnostic yield. A more 
recent study assessed the safety and efficacy of cryobiopsy with RP-EBUS, 
without the use of guide sheath [80] . The authors noted that the most 
significant limitation of the cryobiopsy technique was the rigidity of the 
cryoprobe which could hinder access to PPLs. This was especially the case in 
areas such as the lung apices where the bronchi are highly curved. A cryoprobe 
bending technique which relied on the probe’s shape bending property was 
utilised instead of the guide sheath, to help manoeuvrer the probe. An 
endobronchial blocker was used to limit bleeding. Diagnostic yield from 
histology for cryobiopsies was 86.1% (31/36). Grade 1 bleeding occurred in 25 
patients with grade 2 bleeding occurring in 1 patient only.  
 
1.8.7: Cryobiopsy and Ancillary Testing 
 
Current management and treatment of non-small cell lung cancer (NSCLC) has 
becoming increasingly personalised, depending on identified 
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immunohistochemical and molecular features [81] Having large enough biopsy 
specimens in order to perform these tests and establish appropriate and 
optimal treatment is critical [76, 82]. The ability to perform ancillary testing with 
adequate specimens is particularly relevant with NSCLC which not only 
represents up to 85% of all lung cancer, but typically presents with non-curative 
disease requiring systemic treatment.   
 
The most significant molecular genetic alteration is the EGFR mutation [83]. 
Haentschel et al evaluated that rate of EGFR mutations detected in cryobiopsy 
compared to other biopsy techniques, in pathologically proven NSCLC. 414 
NSCLC patients were included, with cryobiopsy used in 125 (30.2%) cases. 
They confirmed that cryobiopsy increased detection rate with  21.6% (27/125) 
showing EGFR activation mutations, as compared to 13.8% (40/289) in the 
non-cryobiopsy group (p<0.05). The 289 cases in the non-cryobiopsy group 
were sampled by other bronchoscopic techniques (forceps biopsy, FNA 
cytology), radiology guided transthoracic techniques and surgical procedures.  
 
Whilst there was no overall significant difference in detection of these activating 
EGFR mutations from cryobiopsy compared to conventional forceps, 
cryobiopsy was able to detect more EGFR activating mutations in central lung 
tumours compared to conventional forceps (19.6% vs 6.5%, p<-0.05). This was 
a retrospective study, but the first analysis of biopsy technique on EGFR 




Arimura et al assessed tumour cell numbers and PD-L1 expression in a 
prospective study of cryobiopsy and transbronchial forceps biopsies in 16 
NSCLC patients [84]. Their findings demonstrated significantly more tumour 
cells from a single cryobiopsy at 1321 +/- 303.7, compared to forceps biopsies 
at 208.8 +/- 38.24 (p<0.0001). The average number of tumour cells obtained 
with cryobiopsy was also significantly larger (1406 +/- 310.3) than that obtained 
with forceps (208.8 +/-37.81), p=0.0006. Their results suggested that 
performing 1-2 cryobiopsies would provide more DNA for subsequent analyses 
of lung cancers compared to 5 conventional forceps specimens. This could also 
have implications for treatment in patients who had initially been deemed PD-L1 
negative by transbronchial forceps biopsies.  
 
1.8.8: Limitations with Cryotherapy 
 
One recognised limitation with cryobiopsy is the need for the whole cryoprobe, 
with the tissue sample frozen to its tip, to be removed en-bloc with the 
bronchoscope as a single unit. This differs to the conventional method with 
forceps biopsies, where the latter can be removed through the working channel 
of the bronchoscope whilst leaving the bronchoscope in place. Previous studies 
have acknowledged that all patients undergoing cryobiopsy should be intubated 
either with a flexible endotracheal tube or through a rigid bronchoscope [69, 
74]. Obtaining a secure airway means that in the case of any potential bleeding, 
the proceduralist would be able to quickly reinsert the bronchoscope.  In Rubio 
et al’s study [66] however, the investigators were able to safely perform 
bronchoscopy with cryobiopsy using  a supraglottic airway mask in place of an 
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endotracheal tube in order to obtain a secure airway. They noted it served the 
same purpose as the endotracheal tube during bronchoscopy, but also had the 
added benefit of causing less risk of vocal cord or tracheal damage. 
 
1.8.9: Adverse Effects and Complications 
 
Despite previous concerns that extraction of the cryoprobe with tissue frozen to 
its tip would result in tears to the airways and bleeding, cryobiopsy has been 
shown to be comparable and a safe alternative to biopsy with forceps [64, 66, 
68, 69, 73]. 
 
In Rubio et al’s [66] retrospective review of patients being investigated for 
endobronchial disease with either cryobiopsy alone, or in combination with 
forceps biopsy, only one patient was recorded as experiencing minor bleeding. 
In Hetzel et al’s [75] multicentre controlled trial, bleeding events were classified 
depending upon the level of intervention which was required to control it. There 
was, overall, more number of bleeding events which occurred following 
cryobiopsy compared to those who received biopsies with conventional forceps 
(p=0.009). However this was secondary to the increased number of mild 
bleeds. In examining the subset of events where further control was required 
(either argon plasma coagulation laser, tamponade, iced normal saline or 
vasconstrictive medication) there was no difference between the two biopsy 
methods. There was also no difference between the number of patients who 
were on aspirin or clopidogrel. There was no need for surgical intervention and 




The authors attributed the increased mild bleeding seen with cryobiopsy to the 
removal of the cryoprobe and bronchoscope for retrieval of the sample. This 
caused a longer duration for blood to pool at the biopsy site before any control 
could be commenced. This would differ when using conventional forceps 
biopsies where any minor bleeding occurring post biopsy could be suctioned, or 
tamponade to the biopsy site with the scope could be applied immediately, as 
the scope remains in place.  
 
The other major complication concern associated with cryotherapy, in addition 
to bleeding, has been that of pneumothorax. The incidence of this in studies 
assessing cryobiopsy in diffuse parenchymal lung diseases has been quite 
varied, ranging from 0-33% [68-70, 85-87]. In Babiak et al’s retrospective study, 
only 2 patients (4.8%) developed pneumothorax, with the authors finding this 
complication rate quite comparable to that associated with conventional forceps 
transbronchial biopsies [69]. Higher rates occurred in two prospective studies 
by Casoni [86] and Tomassetti [87], both of which investigated cryobiopsy in 
idiopathic pulmonary fibrosis. Casoni et al [86] found that the risk of 
pneumothorax did not correlate either with size of the specimen, or the number 
of samples taken, but did increase if pleura was sampled during the biopsy 
process. They attributed their higher complication rate to the fact that they were 
purposely aiming for biopsy tissue located in a subpleural location. Biopsy at 
proximately 1cm from the chest wall was considered appropriate, for this 
particular population with fibrotic lung disease, in order to achieve maximise 
diagnostic yield. Their group had also previously noted that risk of 
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pneumothorax in fibrotic lung disease, exceeded that in other diffuse 
parenchymal lung diseases [88]. Casoni’s study was also the first to report on a 
death following cryobiopsy. This occurred in an HIV-positive patient who 
required post-procedural chest drain insertion and high flow oxygen for a large 
pneumothorax. The authors felt that this triggered the patient’s acute 
exacerbation, who subsequently died 7 days following the procedure.  
 
In Schuhmann et al’s [71] feasibility study of cryobiopsy for the investigation of 
peripheral lesions, there was only one patient who developed moderate-
severity bleeding. This required only suctioning alone, in order to achieve 
control. There was also no post procedural pneumothoraces observed in this 
study. The authors felt that there were a combination of factors which helped 
reduce the risk of damage to the pleura – use of fluoroscopic guidance, the 
radial sheath assisting to maintain biopsy position, and the fact that only lesions 
visually identified with EBUS underwent biopsy. It does need to be noted 
however, that given that the patients in this study received a combination of 
both different biopsy techniques, results from the safety data could not be 
differentiated as having occurred due to one particular biopsy technique.  
 
1.9: Cryobiopsy versus Surgical Lung Biopsy 
 
Hagmeyer et al [85] were the first to directly compare cryobiopsy and surgical 
lung biopsy in suspected diffuse parenchymal lung disease. Whilst the latter 
technique still remained the gold standard for tissue diagnosis in these 
conditions, the authors wanted to assess situations where patients could not be 
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referred, either due to non-consent, or because of high perioperative risk. A 
retrospective review was performed of 32 patients in whom surgery was not 
appropriate for the above reasons, who underwent cryobiopsy instead.  For 
those whose diagnosis remained equivocal after cryobiopsy, and who had 
declined surgical referral initially, surgery was again re-offered as a step-up 
procedure. Subsequent correlation between histology and other clinical and 
radiological findings were assessed in a multidisciplinary setting. 23/32 cases 
(72%) showed strong congruence. 9 cases had equivocal diagnoses following 
multidisciplinary evaluation with 8 patients subsequently consenting to surgical 
referral. Of these patients, definitive histological diagnosis was ultimately 
achieved in 6 patients (75%), and a probable congruence in 1. 2 of the surgical 
patients died within 30 days secondary to acute exacerbations. Overall, the 
pathological findings from cryobiopsy were thought to be highly congruent with 
surgical biopsies. They did recognise however, because of the latter’s larger 
size, surgery did lead to more definitive diagnosis.  Given their findings, it was 
suggested that transbronchial cryobiopsies were a safe diagnostic tool, 
especially where surgical may not be appropriate. For some patients, it may 
even help remove the need for surgery altogether. 
 
More recently, results of the first prospective study comparing diagnostic 
agreement between cryobiopsy to surgical lung biopsy for the investigation of 
interstitial lung disease (ILD) was published. The COLDICE study [89] is the 
largest study to date, and had co-primary end points of (1) agreement of 
histopathological interpretation between transbronchial cryobiopsy and surgical 
lung biopsy, and (2) agreement between matched cryobiopsy and surgical 
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specimens in determining final consensus clinico-radiological-pathological 
diagnosis at ILD multidisciplinary discussion (MDD). 65 patients with low-
confidence diagnosis or unclassifiable ILD were recruited from 9 Australian 
tertiary hospitals with expertise in both interventional pulmonology and ILD.  
Patients underwent both transbronchial cryobiopsy and surgical lung biopsy 
sequentially, with biopsy information deemed helpful if it changed the degree of 
confidence in diagnosis, or provided an unanticipated diagnosis.  
 
Results from COLDICE confirmed good concordance between surgery and 
transbronchial cryobiopsy in interpretation of histopathology, as well as for 
diagnosis at MDD. In cases where the cryobiopsy diagnosis was deemed 
definite or of high confidence, surgical biopsies provided minimal additional 
diagnostic value. Conversely, for the cryobiopsy cases deemed unclassifiable 
or low confidence diagnosis at MDD, there were only a minority of cases (6/26) 
where addition of surgery subsequently provided a definite or high-confidence 
diagnosis. The study suggested that transbronchial cryobiopsy could therefore 
provide significant diagnostic information, especially in cases deemed to have 
high-confidence ILD pattern and supported its use as a first-line minimally 
invasive option for ILD patients who would otherwise require surgical 
investigation.  
 
Given the study design in COLDICE involved patients undergoing both 
procedures sequentially, it was therefore not possible to directly compare 
safety. Of the 25 adverse events which occurred, only some could be directly 
attributed to cryobiopsy – with mild-moderate bleeding occurring in 14 patients 
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(22%) as well as one incidence of pneumothorax occurring immediately prior to 
surgery. Overall, there were 2 acute exacerbations of IPF, with overall 90-day 
mortality 2%. 
 
1.10: Emerging Bronchoscopic Technologies  
 
1.10.1: Robotic Bronchoscopy 
 
Rojas-Solano et al documented their initial experiences with robotic 
bronchoscopy in a pilot study which assessed technical feasibility using a 
Robotic Endoscopy System (RES)[90]. 15 patients with suspicious lesions 
underwent the procedure under general anaesthesia. The sterile robotic 
bronchoscope was manually inserted into the endotracheal tube, and then 
further advanced to the target lesion using an endoscopy controller. Once the 
lesion was reached, biopsy instruments were passed down the bronchoscope’s 
working channel. There were no events of pneumothorax or significant bleeding 
requiring further intervention. There were three minor complications which were 
not related to the RES. Biopsy was obtained under direct visualisation with the 
RES in 93% patients (14/15). The authors’ primary aim was to assess technical 
feasibility, and the study was therefore not designed to address diagnostic 
yield. As a result, the patients were selected on the basis of a positive BS on 
CT. The absence of significant adverse effects was thought to be multifactorial 
including atraumatic bronchoscope tip, the ability to have precise control of the 
bronchoscope and to lock the scope into a desired position, and thorough 
training of the RES beforehand [90]. The robotic bronchoscope was thought to 
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have improved ability to access more distally located lesions, as opposed to 
conventional bronchoscope given its better column strength and telescoping 
design.  
 
A further study by Fielding et al relayed the first in-human evaluation of another 
novel robotic-assisted bronchoscopic system (Intuitive Robotic Bronchoscope 
System) for patients with PPLs.  Pre-procedural CT scans allowed virtual 
planning, and the proceduralist was able to manoeuvre a robotically controlled 
catheter to the lesion of interest whilst viewing a virtual pathway, in addition to 
live direct airway visualisation from a video probe. The catheter could be 
advanced in all planes of direction, and could also be held still in a specific 
position without slippage and whilst maintaining its angulation. 29 patients were 
included and the primary feasibility endpoint of accessing the PPL and 
subsequent positive histopathological diagnosis from biopsy was met in 29 
patients (96.6%). Similar to the earlier study [90], there were no observed 
pneumothoraces or significant bleeding. This was attributed to the continuous 
visualisation of catheter, its ability to hold position, and the ability of the catheter 
to tamponade the airway, similar to a guide sheath. RP-EBUS was used 
following navigation to confirm lesion location. In comparison to Rojas-Solano’s 
study [90], there only 17 cases in this series (58.6%) who had positive BS on 
CT, with 13 cases (44.8%) having an eccentric image. Mean nodule size was 





These early studies suggested robotic bronchoscopic systems had favourable 
safety profiles, and good capability of accessing PPLs due to their ease of 
manipulation and maintenance of position for sampling.  
 
1.10.2: Cone Beam Computed Tomography (CBCT) 
  
CBCT is an emerging imaging modality typically utilised by interventional 
radiologists [91]. The CBCT system is mounted upon a moving C-arm 
fluoroscopy system which can be orbited around a stationary target (the 
patient). With one single orbit around the anatomic region of interest, an entire 
volumetric dataset can be obtained, and this is used to generate images similar 
to CT-images in real time [92, 93] 
 
A 2018 pilot study combined CBCT technology with thin/ultra-thin bronchoscopy 
to investigate PPLs [92]. The study’s primary aim was to assess radiation 
exposure associated with CBCT; however their secondary aim was to also 
evaluate the utility of CBCT as a navigational and diagnostic tool. “Navigational 
yield” described the proportion of patients where RP-EBUS identified the lesion 
as positive/inconclusive, and CBCT confirmed the radial probe to be in contact 
with lesion. A positive RP-EBUS image was one where the target lesion was 
identified. Aerated lung was considered a negative image, and those images 
not meeting the criteria for positive or negative were considered to be 
inconclusive. Of the 20 patients enrolled, 12 lesions (60%) were fluoroscopically 
invisible. The other 8 were all identified with RP-EBUS, and 6 were confirmed 
with CBCT. Pre-CBCT navigation and diagnostic yields were 50% (10/20). In 
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the remaining 10 patients, further manoeuvring as guided by CBCT to reach the 
lesion that was not identified beforehand increased the navigational yield to 
75% (p=0.02), and the post-CBCT navigational yield was increased to 70% 
(p=0.04).  
 
A subsequent study by Ali et al [93] combined CBCT with VBN and ultrathin 
bronchoscopy for the diagnosis of small PPLs. CBCT findings were categorised 
according to the CBCT target-forceps sign, which was assessed by the position 
of lesion relative to the forceps. Patients were classified as Type A when the 
forceps were seen to reach inside the lesion and Type C when the forceps did 
not access the lesion. Type B encompassed those patients who did not fall 
under Types A or C. Biopsy forceps position was readjusted until there was 
correspondence between the CBCT target forceps sign, and the CT bronchus 
sign. Of the 40 patients enrolled, there were 29 lesions (72.5%) which were 
fluoroscopically invisible, but visible with CBCT. 32 (80%) patients had Type A 
CT BS, and 8 (20%) were classified as Type B. Overall diagnostic yield was 
90%. Yields for CT BS types A and B were 96.9% and 62.5% respectively. 
Diagnostic yields for CBCT target forceps signs Type A, B and C were 100%, 
75% and 0% respectively. In 95% patients, the forceps were able to be 
maneuverered into or adjacent to the target lesion with CBCT, and in this 
regard CBCT was thought to be superior to VBN, or VBN with fluoroscopy. The 
authors concluded that CBCT images contributed not only as a navigational 





1.11: EBUS IMAGE ANALYSIS 
 
Investigation of peripheral pulmonary lesions with RP-EBUS is a well-
recognised bronchoscopic technique.  Its ability to provide information as to the 
position of the miniprobe relative to the lesion, in order to guide biopsy, has 
made it a valued additional diagnostic tool. However the image produced by 
ultrasound has also been studied as to how its features can provide further 
information and potentially clinical data about the lesion’s underlying nature. 
Most of the previous studies addressing analysis of EBUS images have been 
descriptive in nature [94].   
 
Image analysis of EBUS images was used by Kurimoto et al [95] to assess 
whether depth of invasion by tracheobronchial cancers could be determined. 
This knowledge would be of significance, given that level of invasion was an 
important factor in deciding subsequent treatment modality. Kurimoto was not 
the first to report on EBUS analysis of bronchial structure - previous authors 
[43] had also done so, however they did not confirm accuracy by correlating 
their results with histology. Kurimoto recognized that this was imperative, as an 
accurate understanding of the bronchial structure would then assist in correctly 
determining depth of tumour disease. Needle puncture was performed on 45 
surgically resected normal tracheal and bronchi specimens, and 24 specimens 
from patients with lung cancer.  High frequency ultrasonographic examination 
was also performed on the specimens. They were able to demonstrate 5 
distinct layers within both cartilaginous and membranous regions of the 
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tracheobronchial tree, as identified by different imaging features on EBUS. 
Correlation between EBUS image and histopathological findings occurred in 
95.8% (23 of 24 lesions). There was only one case where EBUS overestimated 
depth of invasion.  
 
A subsequent study, also assessing accuracy of EBUS to image the 
tracheobronchial wall and to determine depth of invasion, was reported by Baba 
et al [96].  Their results also supporting those found earlier by Kurimoto [95].  
They studied 61 patients – 21 of which received EBUS during bronchoscopic 
examination in vivo. The other 40 with peripheral tumours or no malignancy had 
resected specimens on which EBUS was performed ex vivo postoperatively. 
Ultrasonographic examination of the bronchi demonstrated 6 different layers 
consisting of epithelium, lamina propropia and submucosa, cartilage layers and 
adventitia. Surrounding structures such as vasculature and lymph nodes could 
also be visualized.  The authors noted that depth of malignant invasion could be 
determined based on disruption of the cartilage layer, but width and size could 
not be determined due to the nature of the radial scanning image. Histologic 
subtype of the tumour could also not be determined by the EBUS.  
 
The first study to report on the internal structure of a peripheral pulmonary 
lesion, in order to improve criteria for distinguishing between benign and 
malignant disease were Kurimoto et al [40]. They performed a retrospective 
review of 124 patients with PPLs who had undergone EBUS, with a subsequent 
definitive histopathological diagnosis obtained. In 69 patients, surgically 
resected specimens were available for correlation. Upon analysing the internal 
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structure of the lesion, Kurimoto was able to identify 3 different classes (or 6 
subtypes) of lesions based on their EBUS pattern for the presence of internal 
echoes, vascular patency, and the morphology of hyperechoic echoes which 
reflected presence of air and the state of the bronchi. 23 of the 25 Type I 
lesions were benign (92%), whilst 98 of 99 Type II and III lesions were 
malignant (99%). Majority of Type II lesions were well differentiated 
adenocarcinomas (21 of 24, 87.5%). The authors noted that the presence of 
hyperechoic dots, when distributed irregularly within the lesions, was 
characteristic of well-differentiated adenocarcinoma, and represented residual 
air in the alveoli which grows to replace the alveolar epithelium. All Type IIIb 
lesions were malignant, of which 18 cases were poorly differentiated 
adenocarcinomas (81.8%) and were seen to be avascular on EBUS image with 
scant mottled or linear hyperechoic areas. The authors concluded that this 
information gained from analysis of the EBUS image of PPLs would be useful in 
speculating its underlying histology.  
 
The issues raised, however, with Kurimoto’s [40] technique was that it relied on 
well-trained operators, and was time-consuming to distinguish between different 
vascular and neoplastic patterns [97].  
 
Subsequently, a later study by Chao et al [97] also investigated the use of 
EBUS in peripheral lesions, but aimed to do so using a more simplified method 
of analysing the EBUS images to speculate on the lesion’s underlying nature. 
151 patients with peripheral lesions were included. EBUS characteristics from 
the first 20 were compared to their tissue diagnosis, and used to train 6 
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experienced bronchoscopists in identifying distinct image characteristics and 
patterns. For the subsequent 131 patients recruited, 2 of the bronchoscopists 
would type the EBUS patterns during the procedure. Where the patterns 
identified were congruent, hard copies of the EBUS image were then sent to an 
independent radiologist reviewer who was blinded to the previous results. Only 
the 126 images with agreeance between all 3 reviewers were included for 
analysis. The authors identified that were generally 4 distinct patterns which 
were easy to identify and type – continuous hyperechoic margin outside the 
lesion, homogenous or heterogenous internal echoes, hyperechoic dots in the 
lesion, and concentric circles along the probe. Images demonstrated 
homogenous internal echoes or concentric circles were more likely to be benign 
lesion by univariate analysis (p=0.001), but only the concentric circles remained 
significant on multivariate analysis. 13 of 16 lesions (81.3%) with continuous 
hyperechoic margins were malignant however there was only a trend towards 
significance with this observation.(p=0.090) 
 
A further study by Kuo et al [98] also aimed to simplify and reclassify the EBUS 
image characteristics earlier described by Kurimoto [40]  into 3 distinct patterns: 
(1) continuous margin; (2) nonlinear, dotted or mottled air bronchogram; and (3) 
heterogenous echogenicity. 224 patients with peripheral lesions were recruited, 
of which 123 had malignant disease, and 101 had benign lesions. Lesions with 
a continuous margin were noted in 27.6% malignant lesions, and 6.9% benign 
(p=0.0001). The air bronchogram pattern observed in 91.9% malignant lesions, 
and 37.6% benign lesions (p=0.0001). Finally, the heterogeneous echogenicity 
pattern was observed in 65% malignant lesions, and 9.9% benign lesions with 
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p=0.0001. The combination of all three patterns was found in 8.9% malignant 
lesions, but not in any of the benign lesions. Conversely, the absence of all 
three features within the lesion was only found in 3.3% malignant lesions, and 
in 59.4% of the benign lesions. They demonstrated a positive predictive value 
for malignancy in a lesion with all three patterns of 100%, whilst the negative 
predictive value for malignancy when no features were present was 93.7%. The 
authors did note that the sensitivity of identified continuous margins in 
predicating malignancy varied depending upon lesion size and probe position. 
The pattern was less accurate in detecting malignancy where the lesion was 
larger than 3cm in diameter or where the probe was adjacent to the lesion, as 
opposed to a lesion diameter smaller than 3cm or with the probe situated inside 
the lesion. The results reiterated the value of EBUS as a diagnostic tool.   
 
All the above studies demonstrating how information from analysis of EBUS 
images could be utilised for clinical practice relied heavily on the operator 
having the ability to identify characteristics patterns. This means that they not 
only relied on an operator’s subjective interpretation of the image, but also their 
previous experience and knowledge with EBUS. Whilst there was often 
congruence between operators in the above studies; they were all expert and 
well trained bronchoscopists or radiologists who were familiar with EBUS.  
 
An alternative and objective method of assessing different features of EBUS 
images is to apply computer-assisted image analysis. This is not a new 
technique. Haralick et al [99] were the first demonstrate application of easily 
computable textural features, as based on their grey-scale, to help categorise 
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or classify pictorial data. They realized that texture was present in all images, 
and developed a class of textural features which examined the relative 
frequency distribution. That is, the features were based on the frequency of 
which one particular grey tone would appear in a specified spatial relationship 
to another grey tone in the image being examined.  
 
Texture of an image was later further defined as the “appearance, structure and 
arrangement of the parts of an object within the image” by Castellano [100]. 
The authors recognized that most medical images were two-dimensional, and 
composed of little blocks or pixels, which could be further analysed to provide 
information about the picture. Consequently, grey scale texture analysis was 
performed on particular regions of interest (ROI) within an image, in order to 
evaluate the pixels and their grey-level of intensity. As established earlier in 
Haralick’s paper [99], the textural features assessed were simply mathematical 
parameters, derived from the  distribution of pixels. Their study confirmed that 
interpretation of the texture features could assist in understanding the 
underlying structure of the object being imaged [100].  
 
Grey scale textural analysis was subsequently applied to ultrasound images of 
pathology within different organs such as breast [101], liver [102], endometrium 
[103] and prostate [104] with success. 
The application of grey scale texture analysis to an EBUS image was first 
described by Nguyen et al [105]. Their study assessed whether computer-
assisted grey scale analysis could be applied to EBUS images to help 
differentiate between malignant and benign lymph nodes. Given the finding by 
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previous researchers that regions of interest <32 pixels2  were associated with 
significant decrease in grey scale texture analysis sensitivity; all of the included 
ROI were greater than 32 pixels2. 151 lymph nodes from 136 patients were 
included, the first 100 of which were used in the prediction set and the 
remaining in the validation set. 18 patients in this validation set also had FDG-
PET-CT results which were available for comparison. 44/51 (86.3%) of the 
nodes within the validation set were able to be classified correctly. When 
comparing grey scale texture analysis to FDG-PET-CT, 16/18 (88.9%) were 
correctly classified according to texture analysis compared to 14/18 lymph 
nodes (778%) with PET scan criteria.  
 
Given that earlier studies into analysis of peripheral pulmonary lesion images 
obtained with RP-EBUS were generally descriptive and required expert analysis 
[97, 98, 106], Nguyen et al subsequently investigated whether greyscale texture 
analysis could be applied to RP-EBUS images to objectively distinguish benign 
from malignant aetiology. They only included images where ultrasound contrast 
and gain settings were set at 4/8 an 10/19 respectively, as any inconsistency 
with image parameters caught would alter subsequent grey scale features. The 
proceduralist captured a single still image, as assessed to be most appropriate 
for performing image analysis of the lesion. Region of interests consisted of 24 
x 24 or 32 x 32 pixel squares which could be placed over the EBUS image, 
depending on the lesion’s size. 167 EBUS-MP images were included for 
analysis – the first 85 in the prediction set, and the following 82 for validation 
set. The prediction set showed that there were three significant greyscale 
features differentiating benign lesions from malignant: increased difference 
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between maximum and minimum pixel values, increased standard deviation of 
the mean pixel values, and increased entropy. Using these features to help 
classify lesions in the subsequent validation set, physician 1 was able to 
correctly classify 63/83 (76.8%) of the lesions, whilst physician 2 correctly 
identified 62/82 (75.6). NPV for malignancy was 100%, and PPV was 71%. 
Again by comparing image analysis results to FDG-PET-CT scan results in 34 
lesions where PET results were available, both physicians identified 27/34 
lesions (79.4%) which was the same as FDG-PET-CT expert opinion.  
 
A similar method of quantitively evaluating EBUS B- mode images was reported 
by Morikawa et al [107] who used histogram-based analysis of brightness of 
EBUS images. They retrospectively reviewed clear EBUS images from 38 lung 
cancer and 22 inflammatory disease patients. For each image, a 400-pixel 
region of interest was chosen and 6 histogram features were analysed: height, 
width, height/width ratio, standard deviation, kurtosis and skewness. Of these, 
height, width, height/width ratio and standard deviation were found to be 
significantly different between malignant and benign lesions. The histogram 
feature with highest diagnostic accuracy was standard deviation. Median 
histogram standard in lung cancer was 11.35 (8.0=14.6) compared to the 
inflammation group with 9.55 (7.3-14.0). Using a cut-off value of 10.5, this was 
found to have sensitivity of 78.9%, specificity 86% and diagnostic accuracy of 
81.7% for the malignant lesions.  
 
The application of image analysis to EBUS images potentially helps provide 
further clinical information to clinicians as to whether the image being studied is 
77 
 
benign or malignant. It will never be a substitute for obtaining tissue diagnosis, 
which would still be the gold standard for confirming evidence of malignancy but 
could be useful to support diagnosis of benign conditions where biopsies are 
negative or equivocal. Conversely, it could provide stronger argument for more 
invasive management such as surgery, in the instances of a negative biopsy 
but high suspicion for malignancy from greyscale analysis and consideration of 
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Abstract
Background: Radial-probe endobronchial ultrasound (RP-
EBUS) is predominantly used clinically for the localisation of 
peripheral pulmonary lesions prior to biopsy. However, the 
RP-EBUS image itself contains information that can charac-
terise the aetiology of lesions. Objectives: The aim of this 
study was to show the utility of RP-EBUS image analysis us-
ing unconstrained regions of interest (ROIs) that utilise more 
image information and eliminate ROI selection bias. Meth-
ods: We developed custom software to analyse RP-EBUS im-
ages digitally captured during clinical procedures. Uncon-
strained ROIs were mapped onto lesions. We computed first-
order greyscale image statistics of minimum, maximum, 
mean, standard deviation and range of pixel intensities, and 
entropy. We also computed second-order greyscale texture 
features of contrast, correlation, energy and homogeneity. 
The results of image analysis were compared to gold-stan-
dard tissue diagnosis. Features from expert- and non-expert-
defined ROIs were also compared. Results: Eighty-five im-
ages were analysed (38 benign and 47 malignant). Five 
greyscale features were significantly different between be-
nign and malignant lesions. Benign lesions had higher mean 
(p < 0.01) and maximal (p < 0.001) intensity, greater range 
(p < 0.001) of pixel intensities and greater entropy (p < 0.01). 
The highest positive predictive values were associated with 
maximal (87.8%) and range of pixel (83.8%) intensities. There 
were no significant differences between expert- and non-
expert-defined ROIs. Conclusion: RP-EBUS image analysis 
using unconstrained ROIs eliminates ROI selection bias and 
can characterise benign and malignant lesions with an ac-
curacy of up to 85%. © 2018 S. Karger AG, Basel
Introduction
Radial-probe endobronchial ultrasonography (RP-
EBUS) is a technique that uses high-frequency ultraso-
nography (20–30 MHz) to visualise peri-tracheal and 
peri-bronchial tissue and structures. Brightness mode 
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properties of the tissue being imaged [1]. It is most com-
monly used for the localisation of peripheral pulmonary 
nodules prior to cytological and/or histological sampling, 
typically via a guide sheath [1–4]. The use of RP-EBUS 
has been shown to significantly improve diagnostic yield 
and reduce complications, such as pneumothorax, when 
compared to computed tomography (CT)-guided biopsy 
of peripheral pulmonary nodules [2, 5–8]. In the hands of 
experts and the controlled environment of research stud-
ies this technique has been shown to have a diagnostic 
yield of up to 87% [2]. However, the real-world data indi-
cates a diagnostic yield of approximately 57% [9]. There-
fore, a significant percentage of patients with peripheral 
pulmonary lesions, even when identified by RP-EBUS, do 
not get a definitive tissue diagnosis. These patients will 
often undergo a repeat attempt at RP-EBUS-guided bi-
opsy or an alternative modality for tissue diagnosis with 
associated morbidity and mortality. Hence, tools that can 
assist in distinguishing lesions as benign or malignant will 
be useful. This is where the use of the RP-EBUS image 
itself is proposed as a novel tool. 
In 2002, Kurimoto et al. [10] first described the clinical 
utility of RP-EBUS image characteristics. Images were 
qualitatively analysed by trained experts to identify image 
types (homogeneous, hyper-echoic dots and linear arcs or 
heterogeneous patterns). These were then sub-typed ac-
cording to the presence or absence of vessels/bronchioles 
or the presence or absence of hyper-echoic dots or short 
lines. Comparing these identified image characteristics to 
resected tissue histology they demonstrated a relation-
ship between the aetiology of lesions and RP-EBUS image 
patterns [10]. Chao et al. [11] presented similar work 
from qualitative analysis of RP-EBUS images to identify 
the presence or absence of 4 image features (continuous 
hyper-echoic margins, internal echoes, concentric circles 
and hyper-echoic dots). They also demonstrated a rela-
tionship between RP-EBUS image features and the aetiol-
ogy of the lesion [11]. Similar work has been presented by 
others [12, 13]; however, these methods all rely on experts 
to subjectively identify image features or patterns. 
To address the subjective nature of prior work, Nguy-
en et al. [14] developed an objective method to analyse 
a b
c d
Fig. 1. a Well-defined lesion with polygo-
nal ROI. b Ill-defined lesion with polygonal 
ROI. c Well-defined lesion with an exam-
ple of a 32 × 32 pixel square ROI. d Ill-de-
fined lesion with an example of a 32 × 32 
pixel square ROI. ROI shown in dashed 


















   
   
   
   
   
   
   
   
   
   
   
























RP-EBUS images. Digitally captured RP-EBUS images 
were used. A small 25 × 25 or 32 × 32 pixel region of in-
terest (ROI) was selected by an expert and analysed using 
a computer to calculate greyscale image statistics and tex-
ture features. They demonstrated that RP-EBUS greyscale 
texture analysis can characterise lesions as benign or ma-
lignant with relatively good sensitivity and specificity 
[14]. Criticisms of their study were, firstly, that the ROI 
was relatively small compared to the total image data 
available and, secondly, that an expert decided where on 
the RP-EBUS image the small ROI should be placed, in-
troducing bias. The aim of our study was to demonstrate 
that RP-EBUS image analysis using unconstrained, 
whole-lesion ROI, can characterise benign or malignant 
aetiology and eliminate issues with ROI selection bias. 
Methods
The study was performed in the Department of Thoracic Med-
icine at the Royal Adelaide Hospital, Adelaide, South Australia. 
The prediction set images from the study by Nguyen et al. [14] (co-
author of the current study) were analysed. Appropriate ethics 
board approvals were obtained as outlined in that study. All RP-
EBUS images were obtained by a group of consultants with at least 
5 years’ experience using EBUS. RP-EBUS images using a contrast 
level setting of 4 (out of a manufacturer maximum level of 8) and 
gain level setting of 10 (out of a manufacturer maximum level of 
19) were captured and saved in an uncompressed file format 
(TIFF). We developed a custom software application using Matlab 
(R2016a, The MathWorks Inc., Natick, MA, USA, 2000) for ROI 
selection, image processing, greyscale statistic and texture analysis, 
and data management. 
ROI Selection and Probe Artefact Exclusion
Following selection of an image for analysis, the user selects the 
centre of the radial probe manually with a mouse click. The soft-
ware then excludes a pre-determined area from the centre of the 
RP-EBUS field, corresponding to RP-EBUS probe artefact, from 
analysis. An unconstrained, polygonal ROI was then drawn over 
the whole lesion (Fig. 1). This ROI was then analysed for the fea-
tures described below. 
Image Statistics and Texture Features
The greyscale image statistics and texture features that were 
calculated have been described previously [14–16]. Briefly, these 
consist of the mean, maximum, and minimum pixel intensity, the 
range (maximum–minimum) and standard deviation of pixel in-
tensities, and entropy (a measure of the degree of disorder in pixel 
intensities). These are collectively termed first-order features as 
they do not contain information regarding the spatial relationship 
of pixels. Second-order features, i.e., contrast, correlation, energy 
and homogeneity, were also calculated. Contrast is a measure of 
the weighted mean difference in neighbouring pixel intensities; 
correlation is a measure of the correlation between pixel intensi-
ties; energy is a measure the variety of pixel intensities, and homo-
geneity is a measure of the frequency of identical pixel intensities 
in neighbouring pixels. These features are collectively termed sec-
ond-order features and require calculation of grey-level spatial de-
pendence matrices as described by Haralick et al. [16].
Tissue Diagnosis
The gold-standard diagnosis was that of tissue diagnosis, ob-
tained by either cytology from brushing, or histology of biopsy 
samples or excised specimens. Lesions were defined as benign 
based on pathology or stability/resolution on surveillance CT chest 
imaging for up to 24 months [14]. The aetiology of the malignant 
and benign lesions is listed in Table 1.
Expert versus Non-Expert 
To test inter-user variability in ROI selection, an expert physi-
cian was asked to draw unconstrained ROIs on areas they felt were 
appropriate for all images in the image set. A second non-expert 
then independently drew unconstrained ROIs for the same imag-
es. The “expert” was a consultant with at least 5 years’ experience 
in using RP-EBUS. The “non-expert” was a trainee with 6 months’ 
experience in using RP-EBUS. In all cases, it was an expert who 
performed the actual EBUS procedure to obtain the image. The 
trainee was only involved in the image analysis part of the project. 
The pixel area, greyscale image statistics and texture features where 
then compared between expert and non-expert selected ROIs.
Table 1. Aetiology of malignant and benign lesions
Malignant Benign 
Pulmonary adenocarcinomas 19/46 (41%) Inflammation, infection or normal lung 20/38 (53%)
Pulmonary squamous cell carcinoma 7/46 (15%) Sarcoidosis or granulomatous inflammation 10/38 (26%)
Non-small-cell lung carcinoma 5/46 (11%) Cryptogenic organizing pneumonia 4/38 (11%)
Small-cell lung cancer 4/46 (9%) Langerhans histiocytosis X 1/38 (3%)
Large-cell lung cancer 1/46 (2%) Eosinophilic pneumonia 1/38 (3%)
Non-pulmonary malignancies 10/46 (21%) Cryptococcal pneumonia 1/38 (3%)
Carcinomas 7 Pulmonary alveolar proteinosis 1/38 (3%)
Melanoma 1
Colorectal adenocarcinoma 1
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Statistical Analyses
All statistical analyses were performed in Matlab (R2016a, The 
MathWorks Inc., Natick, MA, USA, 2000). The median and inter-
quartile ranges were calculated for all features. The Mann-Whit-
ney U test was used to compare greyscale texture features between 
benign and malignant lesions. Receiver-operating characteristic 
(ROC) curves were generated for features that were found to be 
statistically different on Mann-Whitney U test (p < 0.05). The area 
under the ROC curve (aROC), a measure of test accuracy, and the 
optimal cut-off were calculated. An aROC of 0.5–0.7 is considered 
low accuracy, 0.7–0.9 moderate, and > 0.9 high accuracy [14]. RP-
EBUS images were then classified as benign or malignant using the 
optimal cut-off and the result compared to the gold-standard tis-
sue diagnosis. From this, the statistics of sensitivity and specificity, 
and positive and negative predictive values (PPV and NPV, respec-
tively) were calculated. For comparing the expert and non-expert 
ROIs, Pearson’s correlation coefficient and Mann-Whitney U test 
were used to compare ROI pixel area and greyscale texture fea-
tures.
Results
In the study by Nguyen et al. [14], a total of 85 cases 
were used in their prediction set. In total, 47 had malig-
nant and 38 had benign diagnoses. Eight of the benign 
diagnoses were made based on resolution or stability on 
imaging at an interval greater than 12 months and up to 
24 months. In the current study, one of the malignant 
cases had to be excluded from analysis due to a corrupt 
image file. Hence, a total of 46 malignant and 38 benign 
cases were analysed. The majority of malignant cases 
were pulmonary adenocarcinoma, and the majority of 
benign cases were infection/inflammation (Table 1).
Five greyscale texture features were found to be sig-
nificantly different between benign and malignant lesions 
(Table 2). Benign lesions had higher mean (p < 0.01) and 
maximal (p < 0.001) pixel intensity, greater range (p < 
0.001) of pixel intensities, and greater degree of disorder 
(entropy) in pixel intensities (p < 0.01). The minimum 
pixel intensity, standard deviation, contrast, correlation, 
energy and homogeneity were not statistically significant. 
At the optimal cut-offs outlined in Table 3, maximal pix-
el intensity identified malignancy with a sensitivity of 
78.3%, specificity of 86.8% and accuracy of 85%; the range 
of pixel intensities identified malignancy with a sensitiv-
ity of 67.4%, specificity of 84.2% and accuracy of 80%; the 
mean pixel intensity identified malignancy with a sensi-
tivity of 78.3%, specificity of 52.6% and accuracy of 64%; 
the standard deviation of pixel intensities identified ma-
lignancy with a sensitivity of 73.9%, specificity of 74.4% 
and accuracy of 75%; and entropy identified malignancy 
with a sensitivity of 63%, specificity of 73.7% and accu-
racy of 69%. The highest positive predictive values were 
associated with maximal and range of pixel intensities. 
The highest negative predicative values were associated 
with maximal and standard deviation of pixel intensities. 
These results are summarised in Table 3. 
Expert versus Non-Expert 
The results comparing the ROI pixel area and greyscale 
texture features when calculated from ROIs selected by an 
expert and a non-expert are summarised in Table 4. There 
were strong correlations (r > 0.8) and no significant dif-
ferences (p > 0.05) between the ROI area and greyscale 
texture features from ROIs selected by the expert and the 
non-expert. 
Discussion
The current clinical use of RP-EBUS is in the localisa-
tion of peripheral pulmonary lesions prior to biopsy. De-
spite the reported high diagnostic yield of RP-EBUS-
guided biopsy in the literature, the real-world data sug-
gests that diagnostic yield using this technique is likely of 
the order of 60% [9]. Thus, a significant number of pul-
monary lesions identified by RP-EBUS do not have de-
finitive biopsy results to guide management decisions. 
Following appropriate validation of the methods de-
scribed in this paper, the utilisation of RP-EBUS image 
features could support clinical decision-making, particu-
larly in the setting of non-diagnostic/inconclusive biopsy 
results. For example, a patient with a low pre-test proba-
bility of malignancy, a non-diagnostic biopsy, and EBUS 
image features suggestive of benign aetiology could un-
dergo clinic surveillance versus a repeat invasive proce-
dure. Equally, a patient with a high pre-test probability of 
malignancy and non-diagnostic biopsy, with EBUS image 
Table 2. Greyscale statistics and texture features – comparing be-
nign and malignant lesions 
Feature Benign (n = 38) Malignant (n = 46) p*
Maximum 244 (230–255) 199 (163–218) <0.001
Max. – min. 231 (218–255) 186 (153–218) <0.001
Mean 77.5 (52.0–102.8) 61.6 (48.2–74.3) <0.01
SD 34.2 (31.3–41.0) 26.7 (24.7–32.5) <0.001
Entropy 6.9 (6.7–7.1) 6.6 (6.4–6.8) <0.01
Values are medians (interquartile ranges). SD, standard devia-


















   
   
   
   
   
   
   
   
   
   
   
























features suggestive of malignant aetiology, may proceed 
to definitive treatment (e.g., surgical resection) versus a 
repeat invasive diagnostic procedure. Certainly, adding 
RP-EBUS image features to validated nodule assessment 
tools [17, 18] is another possible utility of this methodol-
ogy. 
Multiple studies have demonstrated the utility of RP-
EBUS image features and patterns in classifying periph-
eral pulmonary lesions as benign or malignant [10–13]. 
Most of these studies, however, have been based on sub-
jective assessment of the RP-EBUS images by trained ex-
perts. To our knowledge, only 2 studies to date have 
looked at objective image-based measures. Nguyen et al. 
[14] used small ROIs selected by an expert and analysed 
images for greyscale texture-based measures. Morikawa 
et al. [19] applied a similar methodology but computed 
greyscale histogram-based measures. 
In our study, using unconstrained, whole-lesion ROIs, 
we have demonstrated that greyscale image statistics and 
texture measures can classify lesions as benign or malig-
nant with relatively good sensitivity and specificity. As 
expected, our results mirror those of Nguyen et al. [14] as 
they are based on the same image set. However, addition-
al measures of mean and maximal pixel intensity were 
also included in our analysis and shown to be significant-
ly different between benign and malignant lesions. Im-
portantly, using this approach, we have also shown that 
there is no significant difference in resultant greyscale im-
age statistics and texture features based on ROIs selected 
by an expert or non-expert. 
There are limitations to the work we have presented. 
The sample size is small, without a dedicated validation 
set, and images are limited to those RP-EBUS images with 
constant gain and contrast settings. The latter require-
ment was to ensure consistency with greyscale image 
analysis. Despite showing significant differences, we have 
only presented univariate analyses. The use of logistic re-
gression models that incorporate 2 or more variables to 
improve the diagnostic accuracy is possible. However, 
with our small sample size this type of analysis could yield 
false, misleading results. We were also unable to obtain 
the actual size of the lesions on CT of the chest. An anal-
ysis to investigate if the size of the lesion influences tex-
ture analysis/features is planned for future studies. Also, 
a larger group of experts and non-experts should be test-
ed to verify the inter-user variability in ROI selection.
Probe characteristics and limitations must also be con-
sidered. As address by Morikawa et al. [19], image pixels 
Table 4. ROI pixel area and greyscale statistics and texture features calculated from expert- and non-expert-selected ROIs
ROI pixel area Minimum Maximum Range Mean SD Entropy
Non-expert 5,139 (3,258–8,389) 11 (0–18) 222 (182–252) 214 (162–239) 70.33 (49.83–84.31) 29.35 (24.37–34.20) 6.70 (6.46–6.95)
Expert 5,007 (3,632–8,895) 9 (0–16) 227 (187–252) 217 (177–239) 65.65 (48.96–85.03) 31.78 (24.92–35.24) 6.69 (6.50–7.00)
p* 0.72 0.67 0.76 0.73 0.79 0.44 0.54
r# 0.86 0.90 0.83 0.86 0.96 0.90 0.92
Values are medians (interquartile ranges). ROI, region of interest. * Mann-Whitney U test. # Pearson’s linear correlation coefficient.
Table 3. Greyscale statistics and texture features to differentiate benign and malignant aetiology using the optimal cut-off calculated us-







PPV, % NPV, %
Maximum 0.85 224 78.3 86.8 87.8 76.7
Maximum – minimum 0.80 206 67.4 84.2 83.8 68.1
Mean 0.64 75.6 78.3 52.6 66.7 66.7
Standard deviation 0.75 32.4 73.9 71.1 75.6 69.2
Entropy 0.69 6.7 63.0 73.7 74.4 62.2
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within a 3-mm radius of the centre of the RP-EBUS probe 
are artefact. Equally, image pixels further than a 5-mm 
radius from the centre of the RP-EBUS probe are prone 
to noise due to attenuation of the ultrasound signal. We 
excluded an inner area from analysis to eliminate probe 
artefact; however, we did not exclude image data beyond 
a 5-mm radius. The effect of any significant ultrasound 
attenuation on our data is unclear. 
To address these limitations, a larger dataset is re-
quired. This will also allow validation of the current study 
technique using a separate validation set of images and to 
explore appropriate multi-variate models. Further inves-
tigation of the probe characteristics to test whether re-
striction of the ROIs to 3–5 mm from the probe centre is 
also warranted. To follow up our proof-of-concept study, 
we plan to expand our image analysis set via recruitment 
of further patients from multiple centres within our sci-
entific society.
In conclusion, we have demonstrated that RP-EBUS 
greyscale image statistics and texture analysis using the 
whole lesion as a ROI eliminates ROI selection bias and 
can characterise benign and malignant lesions with an ac-
curacy of up to 85%. With ongoing work and appropriate 
validation, this type of objective, quantitative analysis 
could be a valuable additional clinical tool.
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The incidence of peripheral pulmonary lesions (PPLs) has been steadily 
increasing due to lung cancer screening and rising referrals for imaging. 
Although transbronchial forceps biopsies (TB-FB) has been the conventional 
bronchoscopic approach to tissue diagnosis, yield can be highly variable. 
Cryotherapy has recently provided an alternative biopsy tool. We sought to 
compare transbronchial cryobiopsies (TB-CB) to TB-FB under endobronchial 
ultrasonography (EBUS) guidance in the diagnosis of PPLs.  
Methods 
A prospective, single-centre, randomised controlled trial of patients referred to 
the Royal Adelaide Hospital (RAH) with PPLs suspicious for lung cancer was 
undertaken. Patients were randomised to receive either one TB-CB samples, or 
5 TB-FB samples, with the latter being current standard of care.  
Results 
A total of 28 lesions were evaluated. Overall diagnostic yield was 76.8%. 
Diagnostic yields of TB-CB and TB-FB were 91.7% and 68.8% respectively 
(p=0.14). Median size of TB-CB was 7.0mm compared to 2.5mm with TB-FB 
(p<0.0001). The EBUS probe was seen adjacent to the lesion in 4/28 cases, 
and cryobiopsy provided a positive diagnostic yield in 3 of these 4 lesions. 





TB-CB with EBUS guidance provides larger biopsy specimens with no 
increased risk of major complications. This technique could potentially provide 
increased diagnostic yield in smaller PPLs, and in those lesions which are 




Peripheral pulmonary lesions (PPLs) are focal parenchymal opacities typically 
identified on chest imaging. By definition, a PPL is completely surrounded by 
pulmonary parenchyma and therefore cannot be visualised endobronchially 
during bronchoscopic examination [3]. The main concern regarding these 
lesions is their potential to have an underlying malignant aetiology. Obtaining 
tissue is the only definitive method to confirm diagnosis and transbronchial 
biopsy is the most conventional bronchoscopic method for doing so. However, 
even when performed under fluoroscopic guidance and combined with other 
sampling procedures such as bronchial washings and brushings, diagnostic 
yield can still be highly variable [20, 21].  
The introduction of endobronchial-ultrasonography with a guide-sheath (RP-
EBUS) has helped to further improve diagnostic yields, allowing real time 
visualisation of the bronchoscope location [18]. However, an inherent feature 
related to forceps sampling is the small biopsies sizes obtained. Tissue 
samples are also often subjected to forceps crush artefact which can result in 
poor preservation, or alteration of cellular architecture which can adversely 
affect histopathologic analysis [64, 67, 69].  
Given these limitations of forceps biopsies, more recent attention has been 
given to cryotherapy. Cryoprobes have been utilised as early as the 1970’s 
where they were primarily used a debulking tool [64]. Subsequent modifications 
in cryotherapy technology have produced greater freezing power and increased 
tensile strength allowing it to be used for its adhesive effects.  Tumours 
extracted with this technique have been observed to be of remarkably good 
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size and quality, despite being frozen and unfrozen [64]. This has led to 
cryoprobes being utilised for transbronchial cryobiopsies (TB-CB). The 
reassuring safety profile of TB-CB in diffuse parenchymal lung disease has led 
to the increasing use of cryoprobes in the investigation of PPLs, and it has been 
hypothesised that the larger specimens obtained may provide higher diagnostic 
yields. 
In this randomised controlled trial, we therefore sought to evaluate the use of 
cryoprobes compared to conventional forceps biopsy in the investigation of 
PPLs. We aimed to demonstrate that TB-CB would produce larger specimens 
and consequently, higher diagnostic yields when compared to conventional 
standard forceps biopsies. We also aimed to demonstrate higher diagnostic 
yields in lesions which were not easily accessible with traditional forceps.  
METHODS 
Study Population 
This was a prospective, randomised single-centre study performed at the Royal 
Adelaide Hospital (RAH) in Adelaide, Australia. Patients referred for 
investigation of a peripheral lesion which was suspicious for malignancy were 
eligible for participation, whereby current standard of care would typically 
involve performing tissue sampling via RP-EBUS. We excluded patients who 
had endobronchial disease or mediastinal lymphadenopathy. Eligible patients 
were randomised to either TB-CB or conventional TB-FB with a computer-
generated randomisation schedule. Patients provided signed written consent 
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and ethics approval was granted by the Royal Adelaide Hospital Ethics 
Committee. 
Procedure 
Procedures were performed in the Thoracic Procedure Suite at the RAH by 
respiratory registrars under the supervision of an experienced interventional 
pulmonologist. Those patients undergoing conventional RP-EBUS alone were 
typically performed using local sedation (intravenous midazolam and fentanyl) 
or under general anaesthesia. TB-CB were all performed under general 
anaesthesia.  
Navigation was performed pre-procedure with CT analysis, using Kurimoto’s 
bronchial branch mapping method to locate the lesion.  
Procedures were performed using the radial EBUS probe (K-201/K-203; 
Olympus, Tokyo, Japan), under fluoroscopic guidance. Following EBUS 
visualisation of the lesion, the miniprobe was removed with the guide-sheath 
left in place. Patients randomised to the control group received 5 conventional 
TB-FB samples, whereas those in the cryotherapy arm received one TB-CB 
samples (ERBE 1.9 cryoprobe; Germany). The cryoprobe was passed via the guide-
sheath (2/2.6mm channels). There was a freeze time of 5 seconds, and the bronchoscope was 
subsequently removed en-bloc. All patients also received bronchial washings and 
brushings prior to biopsy as per standard of care.  
All TB-CB arm patients were intubated via endotracheal tube (Rusch 
Bronchoflex), which had two ports, allowing both bronchoscope and a balloon 
blocker catheter to be passed down simultaneously. The latter could then be 
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inflated under direct vision to tamponade any potential bleeding whilst the 
bronchoscope was being removed to retrieve the biopsy.  
Any difficulty in accessing a lesion was considered a failed procedure. In cases 
where the cryoprobe was initially used, the operator would revert to standards 
methods with forceps to re-attempt biopsy.  
Statistical Analysis 
Continuous variables are described as mean and standard deviation or median 
and interquartile range as appropriate to distribution, and dichotomous 
variables as number and percentage. Baseline characteristics in both groups 
were compared with Student t tests or Wilcoxon rank-sum tests for continuous 
variables as per distribution and chi square tests for dichotomous variables. 
Outcomes in both groups were compared with chi square tests. Analyses were 
undertaken with Stata version 13.0 (Stata Corporation) and statistical 
significance set at 0.05.  
RESULTS 
Patient Characteristics 
A total of 32 patients were recruited (19 males; Figure 1 and Table 1). Fifteen 
patients were randomised into the cryotherapy arm and 17 were randomised to 
conventional TB-FB. Three patients in the cryotherapy group were 
subsequently excluded. One of these patients was found to have FDG-avid 
lymphadenopathy on PET scan with linear EBUS being performed instead. A 
further two patients were excluded as their lesions were found to have resolved 
on CT by time of the procedure. Two patients who were randomised to the 
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cryotherapy arm did not undergo TB-CB as one lesion was located too proximal 
for safe biopsy, and in the second patient it was not possible for the cryoprobe 
to be maneuvered into the correct airway. In the conventional forceps group, 
one case was excluded due to resolution of lesion on CT. As a result, a total of 
28 patients were retained for analysis. The mean ages of participants in the 
cryotherapy and forceps arms were similar at 63 +/- 13 years and 64 +/- 17 
years respectively.  
Lesion Characteristics 
Average dimensions of the TB-CB lesions were 19x21 millimetres compared to 
25x23 millimetres in the TB-FB arm (p=0.71 and 0.22 for shortest and longest 
dimensions respectively; Table 1). Median lesion area in the cryotherapy arm 
was slightly smaller compared to the conventional forceps group (360 [IQR 192-
800] versus 459 [IQR 276-1012] mm2, p=0.38). Distance from the pleura was 
also very similar between lesions being biopsied in both arms, with median 
distances of 10 (IQR 3-30) and 8 (IQR 3-30) mm in the cryotherapy and forceps 
groups respectively (p=0.94). 50% of participants had lesions located within the 
right upper lobe, and 25% had lesions within the left upper lobe. The remainder 
of lesions were found within the right lower lobe, lingula and left lower lobe.  
Biopsy Characteristics 
Measurement of biopsy sample sizes confirmed that cryobiopsies were 
generally larger with median biopsy size 7 (IQR 2-22) mm, and with a greater 
range in biopsy sizes, as compared to the forceps group which had median size 
2.5 (IQR 1-5) mm (p<0.0001). 
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The EBUS probe was observed to be within the lesion in 22/28 patients. The 
lesion was seen to be adjacent to the probe in 4/28 patients, with 3 of these 
patients having been randomised to cryobiopsy. In 2/28 patients, the lesion 
could not be identified.  
Diagnostic Yield 
The overall diagnostic yield was 78% (22 out of 28 patients). A numerically 
higher diagnostic yield of 91.7% (11 out of 12 patients) was demonstrated with 
cryotherapy compared to the forceps group (68.8%, 11/16 patients), however 
this did not reach statistical significance (p=0.14).  
Where the lesion was visualised with EBUS, cryotherapy again demonstrated a 
numerically higher yield compared to forceps (Table 2). Of the 2 lesions which 
could not be identified by EBUS, a diagnosis was still achieved nonetheless in 
the one patient randomised to cryobiopsy.  
When the probe was seen within the lesion, TB-CB had diagnostic yield of 
87.5% (7 out of 8 patients), as opposed to 71.4% (10 out of 14 patients) 
(p=0.61). In the 4 patients where the lesion was seen adjacent to the probe, of 
which 3 were randomised to cryotherapy, a diagnosis was achieved in all 
cases.  
There appeared to be a trend towards increased diagnostic yield for cryobiopsy 
of lesions located within the left upper lobe (p=0.053). 
A total of 22 of 28 lesions were found to be malignant, with 13 (47%) confirmed 
as pulmonary adenocarcinoma. The remaining 6 patients (21%) had benign 
aetiology with evidence of infection or inflammation on biopsy. Diagnostic yields 
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for malignant and benign lesions were both higher with TB-CB, although this did 
not reach statistical significance. Positive predictive value for malignancy 
overall and with TB-CB were 100% respectively.  
A small subset of patients randomised to cryotherapy also received TB-FB 
biopsies in addition to their one TB-CB at the discretion of the proceduralist, 
thus allowing a direct comparison of the biopsy technique in the same patient. 
There were 3 patients in whom TB-CB provided a diagnosis whereas 
conventional TB-FB was inconclusive. Conversely, there were 4 patients where 
a diagnosis was not obtained by TB-CB, but was confirmed with the forceps. In 
2 of these 4 cases, TB-CB could not be performed due to the lesion being 
located too proximal for safe biopsy, or where the cryoprobe could not be 
maneuvered into the correct airway. 
For lesions where a diagnosis was diagnosed only via cryobiopsy, median 
lesion size as measured from CT imaging was 117 (IQR 114-225) mm2. In 
comparison, there was a median size of 619 (869-7324) mm2 for those lesions 
in which a diagnosis was only achieved via forceps, and not via cryoprobe. 
Repeat Procedures and Complications  
Further diagnostic procedures were required in 7 patients. 3 patients with non-
diagnostic TB-CB were referred on for CT-guided biopsy. Of the 4 patients with 
negative TB-FB results, 2 were referred for CT-guided biopsy, one patient 




The most common complication observed was bleeding, with incidence of 
28.6% in cryotherapy group, and 3.6% with TB-FB. However, these were all 
relatively mild and resolved with the used of suction, iced normal saline and/or 





In this randomised controlled trial, we compared the use of TB-CB to 
conventional TB-FB in evaluating PPLs with the use of RP-EBUS. Cryotherapy 
produced significantly larger biopsy sizes. Whilst there was a numerically higher 
diagnostic yield within the cryotherapy group, this did not reach statistical 
significance. The overall diagnostic yield of 78% from our cohort, was very 
much in keeping with the historical diagnostic yield at the Royal Adelaide 
Hospital. For the proceduralist involved, historically his overall yield was 70-
80% over many yearsfor transbronchial biopsies. There was no difference in 
the incidence of major complications.  
Investigation of PPLs 
The incidence of peripheral pulmonary lesions has been steadily increasingly, 
particularly with increased usage of computed tomography imaging generally, 
and also due to lung cancer screening [8, 71, 108]. Results from the recent 
National Lung Screening Trial demonstrated a 20% relative reduction in lung 
cancer mortality when participants underwent annually screening with low-dose 
CT [8]. 
For over 40 years, bronchoscopy has had a pivotal role in the investigation of 
PPLs [18]. However, its success relies significantly upon the bronchoscopist’s 
ability to navigate the bronchial system and obtain samples successfully from 
the target lesion. Even with the assistance of fluoroscopy, diagnostic yield for 
transbronchial biopsies is highly variable. For nodules less than 2 centimetres, 
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sensitivity can be as low as 14% [23, 33]. The introduction of radial EBUS has 
not only been useful for smaller lesions which are fluoroscopically invisible [18, 
39, 40],  but has also allowed for an increased reliability and yield of the 
sampling through use of the guide sheath.  
Schuhmann et al [71] were the first to evaluate safety and feasibility of radial 
EBUS with cryobiopsy in peripheral lesion. 39 patients were enrolled to receive 
both forceps transbronchial biopsies and cryobiopsies, with the order 
determined by randomisation. They reported overall diagnostic yield of 60.5% 
(23/39 patients), which increased to 74.2% when accounting for lesions 
visualised by EBUS (23/31 patients).  
EBUS visualisation was already known to be strongly associated with 
diagnostic yield [3, 18, 25, 39, 44, 45, 47, 50] In the first randomised trial of RP-
EBUS versus CT-guided biopsy, Steinfort et al not only demonstrated increased 
yield with EBUS visualisation (100% vs 50%), but that EBUS visualisation was 
also significantly associated with a subsequent diagnosis of lung cancer [1]. 
Our study did not demonstrate any overall difference in diagnostic yield 
between TB-CB and TB-FB, which is not dissimilar to previous studies using 
RP-EBUS guidance [71, 76, 77]. Although there was improved diagnostic yield 
for TB-CB with positive EBUS visualisation, this did not meet statistical 
significance.  
Our protocol differed to Schuhnann et al’s in that patients were otherwise 
randomised to either TB-CB or TB-FB.  Whilst there were 7 patients who 
received both biopsy methods at discretion of the proceduralist, there were too 
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few cases in this subset to definitively compare diagnostic yield. A diagnosis 
was achieved via only TB-CB in 4 of these patients, and only TB-FB in the other 
3. Nasu et al [76] had similar results where 7 patients were positive on forceps, 
but negative on cryobiopsy. Their study differed in that TB-CB was performed 
without guidesheath. The authors commented on difficulty advancing the 
cryoprobe where there were multiple airways, and there was thus a possibility 
that TB-CB was not obtained from same site as TB-FB.  This was the case with 
one patient in our study where the probe could not be properly introduced in to 
the correct airway. It was notable in our study that lesions in which only 
cryobiopsy was successful were of markedly smaller size, when measured from 
CT imaging.  
The position of the radial EBUS probe in relation to the lesion as seen during 
bronchoscopy was also recorded as this has previously been demonstrated to 
be an important factor influencing diagnostic yield [47, 50]. Yamada et al [50] 
showed this to be the only significant factor on multivariate analysis for lesions 
smaller than 3 centimetres. Kho et al [77] specifically assessed the 
performance of TB-CB in eccentrically and adjacently-orientated PPLs. They 
showed cryobiopsy increased diagnostic yield in adjacent lesions from 22% to 
66.7%, although this also did not reach significance. The advantage of the 
cryoprobe is its ability to obtain a sphere of frozen tissue, hence taking lateral 
biopsies as opposed to just sampling in a forward direction [71, 78]. In Kho et 
al’s study, 57.2% of inconclusive TB-FB were found to be bronchial epithelium, 
likely due to the inadequate depth of lateral biopsy [77]. In our cohort, there 
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were 4 patients where the probe was seen adjacent to the lesion. A diagnosis 
was achieved in all, with 3 of these 4 undergoing cryobiopsy. 
It is not unusual to have increased episodes of mild bleeding with cryobiopsy, 
as reported in a large multicentre trial by Hetzel et al [75]. This was attributed to 
the need for the whole removal of the cryoprobe and bronchoscope en-bloc, for 
retrieval of the sample, resulting in a longer duration for blood to pool at the 
biopsy site. This was opposed to conventional forceps where any minor 
bleeding could be suctioned/tamponaded immediately whilst the scope 
remained in place. Our study showed consistent results with increased 
incidences on bleeding, but with only minimal intervention required in all cases. 
. Similar to Schuhmann’s feasibility study, there was no pneumothoraces in our 
patients. Factors minimising risk of damage to the pleura likely included use of 
fluoroscopy, use of the radial sheath, and that only lesions visually identified 
with EBUS were biopsied.  
Study Limitations 
There were several limitations to our study. Complete blinding of investigators 
and participants to randomisation was not possible, due to the need for TB-CB 
to be performed under general anaesthesia. Our sample size was also small 
and therefore not powered to demonstrate superiority. Longer waiting times for 
availability on a general anaesthetic list at our institution impacted our ability to 
recruit. It was not appropriate for potential participants to wait longer for the 
purposes of this trial, if they could access TB-FB with local sedation in a timely 
manner, especially given concern for underlying malignancy.  
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Our study was commenced prior to the availability of newer disposable 
cryoprobes with their thinner 1.1 millimetre diameter, which could be passed 
through the thin guide sheath channels. These could provide improved 
manoeuvrability, facilitate more accurate placement and further improve 
diagnostic yield.  
CONCLUSION 
In conclusion, our study confirmed that cryobiopsy provides larger biopsy 
specimens and could potentially be more useful in smaller peripheral lesions, 
and those which are more difficult to access such as those located adjacent to 
the probe. Furthermore, we observed no increase in major complications, 
Cryobiopsy may therefore provide an alternative method to investigating PPLs. 
Further prospective randomised trials, with larger participants numbers, would 
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 Forceps Biopsy Cryobiopsy p-value 
Patients    
Age 64 +/- 17 63 +/- 13 1.00 
Gender    
- Male 10 (58.8) 9 (60.0) 0.95 
- Female 7 (41.2) 6 (40.0)  
Lesion    
Size 25x23 19x21  
Area (mm2) 459 (275-1012) 360 (192-800) 0.38 
Distance from 
pleura (mm) 





 Forceps Biopsy Cryobiopsy p- value 
Biopsy Method 68.8 (11/16) 91.7 (11/12) 0.14 
    
EBUS visualisation of lesion    
Positive 73.3 (11/15) 90.9 (10/11) 0.26 
Negative  0 (0/1) 100 (1/1) 1.00 
    
Probe Position    
Within Lesion 71.4 (10/14) 87.5 (7/8) 0.61 
Adjacent to Lesion 100 (1/1) 100 (3/3) - 
    
Diagnoses    
Malignant  66.7 (8/12) 90.0 (9/10) 0.19 










CHAPTER 4: FINAL DISCUSSION, LIMITATIONS AND CONCLUSION  
This thesis has examined aspects related to the investigation of peripheral 
pulmonary lesions, the incidence of which continues to rise with increased CT 
imaging and with lung cancer screening.  This is of particular relevance in 
Australia where lung cancer is not only the fifth most commonly diagnosed 
cancer, but also contributes to the most number of cancer-related deaths.  
Whilst there are several well-established international guidelines regarding 
management and potential surveillance of these lesions, obtaining tissue is the 
only way for obtaining an accurate diagnosis.  As survival rates fall with 
advanced disease, the ability to identify lung cancer early is critical to preserve 
quality of life and survival. 
The aim of this thesis was to evaluate alternative investigative techniques which 
could be used alongside conventional transbronchial forceps biopsies, in the 
bronchoscopic investigation of peripheral lesions.  
In Chapter 2, we demonstrated how objective greyscale analysis of RP-EBUS 
images could further assist in differentiating benign from malignant disease. 
This is particularly relevant in patients with the former, who might be saved from 
unnecessary repeat invasive procedures in the situation where there is no 
evidence of malignancy demonstrated on initial sampling.   
Our study involved assessment of 84 RP-EBUS images for image analysis. 46 
lesions had underlying malignant aetiology. We identified five greyscale 
features which were found to significantly differ between benign and malignant 
lesions. By utilising the RP-EBUS image of the (unconstrained) whole lesion as 
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region of interest, this method could differentiate lesions with diagnostic 
sensitivity up to 78%, specificity up to 86% and positive predictive values up to 
88%. The highest positive predictive values were seen with maximal pixel 
intensity and range of pixel intensity.  
Whilst the current use of RP-EBUS is to aid the bronchoscopist as to the 
optimal biopsy site, the RP-EBUS image itself has also been shown to provide 
further clinical information regarding the lesion’s underlying nature. Earlier 
studies demonstrated that this information could be utilised in clinical practice, 
however to do so relied solely on the operator’s subjective ability to identify and 
interpret image characteristics, as well as their previous experience and 
knowledge with RP-EBUS. However, it is recognised that digital images contain 
more information that can be perceived by the human eye.  Our results 
reiterates earlier findings that application of computer-assisted image analysis 
could provide an alternative and more objective method of assessing different 
features of these EBUS images.  Greyscale texture analysis had already been 
successfully applied to ultrasound images of pathology in non-pulmonary 
organs. It was then successfully used to objectively distinguish benign from 
malignant aetiology in the analysis of RP-EBUS images. Our study progressed 
from previously demonstrated results by using a larger, whole-lesion, 
unconstrained region of interest. We hypothesised that the larger unconstrained 
ROI would not only provide more pixel information, but would also reduce ROI 
selection bias and thus be less dependent on user expertise.  
Whilst we recognise histology remains the gold standard in diagnosis, 
greyscale image analysis could further aid clinical decision making. This would 
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be especially relevant in situations where there is uncertainty regarding 
adequacy of biopsy samples, with inconclusive or non-diagnostic results.  
Chapter 3 further investigated the utility of cryobiopsy as an alternative biopsy 
to conventional forceps for sampling peripheral lesions. Whilst bronchoscopy 
has been a fundamental tool in the investigation of peripheral lesions, its 
success relies heavily on the proceduralist’s ability and diagnostic yield can be 
highly variable. Sensitivity also correlates to the size of the target lesion, and is 
lower with smaller nodules.  The introduction of radial EBUS improved 
diagnosis in smaller and even fluoroscopically-invisible lesions. However an 
inherent feature of these forceps biopsies samples was their small size, and 
predisposition to crush artefact.   
Initially, transbronchial cryobiopsies had primarily been used for the evaluation 
of diffuse parenchymal lung diseases. In light of their favourable safety profile, 
we have recently seen increasing data regarding its use for peripheral lesions. 
We aimed to demonstrate that cryobiopsy with RP-EBUS would provide larger 
biopsy specimens compared to conventional forceps. This was essential not 
only for improved diagnostic yield, but also for guiding further immuno-
histochemical, and molecular analysis which may be relevant for treatment.  We 
also hypothesised that cryobiopsy might have increased diagnostic yield in 
lesions which  were typically difficult to biopsy with conventional transbronchial 
forceps.  
Our results confirmed  that much larger biopsy sizes could be achieved with 
cryotherapy compared to that with forceps, with median sizes  7mm and 2.5mm 
respectively (p<0.0001). Of the 28 lesions evaluated, there was overall 
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diagnostic yield of 76.8%. There was a trend towards improved diagnostic yield 
with TB-CB than TB-FB. In particular, our results suggested that cryotherapy 
could potentially be of increased utility in patients with smaller lesions, or those 
which were difficult to access. 
There are limitations to both studies in Chapter 2 and 3. The image analysis 
study in Chapter 2 was only of small sample size with images limited to only 
those RP-EBUS images with constant gain and contrast settings. Whilst 
significant differences were seen on univariate analysis, it is possible that 
multivariate analyses could provide improved differentiation between malignant 
and benign disease.  We acknowledge that the user would still be required to 
have some understanding of interpreting RP-EBUS images in order to draw the 
region of interest, and the analysis could only occur post-procedure. This 
method did not currently assist a proceduralist real-time during a procedure.  
Further studies with larger datasets, separate validation sets and further multi-
variate analysis would be of benefit to validate the applicability of this method 
further. Similarly, larger number of experts and non-experts would also provide 
more information regarding the inter-user variability or region of interest 
selection.  
Our study on transbronchial cryobiopsy in Chapter 3 was also limited by small 
sample size. As cryobiopsy patients required their procedure to be performed 
under general anaesthesia with potential longer waiting times for investigation, 
this had significant impact on our ability to recruit all suitable patients.   As the 
study was performed in a single tertiary referral hospital, it is also possible that 
the generalisability of these findings is limited. Larger prospective, multi-centre 
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trials would be required to further clarify the potential superiority of cryobiopsy 
in the management of these patients. Future directions could also include 
comparison of different sized cryoprobes, assessing adequate number of 
cryobiospy samples, and further evaluation of its use in lesions which are 
typically difficult to sample via conventional transbronchial forceps.  
In conclusion, the timely management and accurate diagnosis of the peripheral 
pulmonary lesion will continue to be critical for respiratory physicians in order to 
maintain best patient outcomes.  Whilst there can be wide variety in how these 
lesions are approached with multiple different international guidelines available,  
obtaining tissue remains the gold standard for diagnosis. This thesis has 
explored the different bronchoscopic methods for sampling target lesions. We 
have shown the advantage of cryotherapy in providing larger sample sizes with 
similar safety profile to transbronchial forceps biopsies. Furthermore, we have 
demonstrated the value and accuracy of greyscale image analysis, which could 
be especially useful as an adjunct, particularly if there is uncertainty regarding a 
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